Epigenetic control of alveolar fluid clearance

Inauguraldissertation
zur Erlangung des Grades eines Doktors der Humanbiologie
des Fachbereichs Medizin
der Justus-Liebig-Universität Gießen

vorgelegt von Łukasz Andrzej Wujak
aus Thorn, Polen

Giessen, 2014
Aus dem
Max-Planck-Institut für Herz- und Lungenforschung, Bad Nauheim
Leiter/Direktor: Prof. Dr. Werner Seeger

Gutachter: Prof. Dr. med. Markus Weigand

Tag der Disputation: 12. Juni 2014
I. Table of contents

I. Table of contents .................................................................................................................. 1

II. List of figures .......................................................................................................................... 4

III. List of tables .......................................................................................................................... 6

IV. List of abbreviations ............................................................................................................. 7

1. Introduction .......................................................................................................................... 10

1.1. Acute respiratory distress syndrome .............................................................................. 10

1.1.1. Pathology of acute respiratory distress syndrome ...................................................... 11

1.1.2. Injury to the alveolar-capillary barrier promotes edema formation and persistence in acute respiratory distress syndrome ................................................. 12

1.2. Alveolar fluid clearance ..................................................................................................... 14

1.2.1. Alveolar fluid clearance is impaired in acute respiratory distress syndrome ......... 16

1.2.2. Upregulation of alveolar fluid clearance can improve acute respiratory distress syndrome ...................................................................................................... 17

1.3. Transforming growth factor-β signaling ........................................................................ 19

1.3.1. Function of SMAD proteins in the transcriptional regulation of gene expression .......... 20

1.3.2. SMAD-associated transcription factors and transcription co-factors ......................... 22

1.3.3. Epigenetic mechanisms in TGF-β-dependent gene regulation ................................. 23

1.4. The role of TGF-β signaling in acute respiratory distress syndrome ....................... 25

2. Hypothesis and aims of the study ..................................................................................... 27

3. Materials and methods ........................................................................................................ 28

3.1. Materials .......................................................................................................................... 28

3.1.1. Technical equipment .................................................................................................... 28

3.1.2. Chemicals and reagents ............................................................................................. 29

3.1.3. Cell lines ..................................................................................................................... 32

3.2. Methods .......................................................................................................................... 33

3.2.1. Human lung material ................................................................................................. 33

3.2.2. ATP1B1 promoter cloning ......................................................................................... 33

3.2.2.1. Sub-cloning of the ATP1B1 promoter from the pGEM-T Easy vector into the pGL3-Basic vector ................................................................. 33
3.2.2.2. Plasmid transformation of competent cells .................................................. 34
3.2.2.3. Plasmid midi-preparation ................................................................................. 34
3.2.3. A549 cell culture ......................................................................................... 35
  3.2.3.1. Treatment of A549 cells ........................................................................... 35
  3.2.3.2. Transient transfection of short interfering RNA ....................................... 35
  3.2.3.3. Transient transfection of DNA ................................................................ 36
3.2.4. Culture of primary mouse alveolar epithelial type II cells ....................... 37
  3.2.4.1. Isolation of primary mouse alveolar epithelial type II cells ................. 37
  3.2.4.2. Treatment of primary mouse alveolar epithelial type II cells ............ 38
3.2.5. Dual-luciferase reporter assay ................................................................. 38
3.2.6. Gene expression analysis ........................................................................... 38
  3.2.6.1. RNA isolation from lung tissue and from cell culture ......................... 38
  3.2.6.2. cDNA synthesis ....................................................................................... 39
  3.2.6.3. Real-time quantitative PCR ................................................................. 40
3.2.7. Protein expression analysis ........................................................................ 41
  3.2.7.1. Protein isolation ....................................................................................... 41
  3.2.7.2. Protein electrophoresis and western blot .......................................... 41
3.2.8. Chromatin immunoprecipitation ............................................................. 43
3.2.9. Animal experiments .................................................................................. 45
  3.2.9.1. The bleomycin model of acute respiratory distress syndrome
            and trichostatin A treatment ........................................................................ 45
  3.2.9.2. Lung tissue collection and weight measurements ................................ 45
  3.2.9.3. Broncho-alveolar lavage ................................................................. 46
  3.2.9.4. Measurement of protein concentration in broncho-alveolar
            lavage fluid ................................................................................................. 46
  3.2.9.5. Analysis of inflammatory cell populations ........................................ 46
  3.2.9.6. Evans blue extravasation assay ......................................................... 47
3.3. Statistical analyses ..................................................................................... 47

4. Results .............................................................................................................. 48
  4.1. Pulmonary expression of genes encoding Na,K-ATPase subunits in
       lungs from acute respiratory distress syndrome patients and in
       healthy lung tissue .......................................................................................... 48
  4.2. TGF-β alters the expression of genes encoding Na,K-ATPase
       subunits in A549 cells .................................................................................. 49
Table of contents

4.3. Inhibition of TGF-β signaling restores ATP1B1 gene expression .......... 50
4.4. TGF-β downregulates ATP1B1 gene expression via SMAD2, SMAD4, SNAI1 and E2F5 transcription factors ........................................ 51
4.5. TGF-β downregulates ATP1B1 promoter activity ................................. 53
4.6. The TGF-β-dependent down-regulation of ATP1B1 gene expression is mediated by DNA methylation and class I histone deacetylases ........... 54
4.7. Histone deacetylase 2 mediates repression of the ATP1B1 gene by TGF-β ........................................................................................................ 56
4.8. Histone deacetylase 2 occupies the ATP1B1 promoter and is activated by TGF-β .................................................................................................. 57
4.9. Downregulation of the Atp1b1 gene in TGF-β-stimulated alveolar epithelial type II cells can be reversed by inhibition of class I histone deacetylases .................................................................................. 59
4.10. Histone deacetylase inhibition rescues Atp1b1 gene expression and decreases lung water content in the bleomycin model of acute respiratory distress syndrome ................................................................. 60
4.11. Trichostation A does not decrease alveolar-capillary barrier permeability in bleomycin-treated mice ................................................................. 61
4.12. The inflammatory response is not modified by histone deacetylase inhibition in the bleomycin model of acute respiratory distress syndrome ........................................................................................................... 62

5. Discussion .............................................................................................................. 64
5.1. The expression of the ATP1B1 gene is strictly regulated by TGF-β .......... 65
5.2. TGF-β signaling employs epigenetic machinery to regulate the ATP1B1 gene ........................................................................................................... 66
5.3. The inhibition of histone deacetylases rescues Atp1b1 gene expression and reduces pulmonary edema ........................................................................ 68

V. Summary ................................................................................................................. 72
VI. Zusammenfassung .................................................................................................. 73
VII. Literature ............................................................................................................. 74
VIII. Acknowledgements ............................................................................................ 83
IX. Curriculum Vitae ................................................................................................ 84
X. Declaration ............................................................................................................ 86
II. List of figures

Figure 1. Comparison of a healthy alveolus to a damaged alveolus in the acute phase of acute respiratory distress syndrome. ........................................ 12
Figure 2. Architecture of the Na,K-ATPase. .......................................................... 15
Figure 3. Mechanisms of perturbed alveolar fluid clearance leading to the formation and persistence of pulmonary edema after lung injury. .................................................................................. 17
Figure 4. Strategies for improving Na⁺ transport and edema resolution in acute respiratory distress syndrome. ......................................................... 18
Figure 5. Overview of the TGF-β signaling pathway. ............................................. 21
Figure 6. Pulmonary expression of genes encoding Na,K-ATPase subunits in donor versus ARDS patients. ................................................................. 48
Figure 7. Expression of genes encoding Na,K-ATPase subunits in TGF-β-treated A549 cells.......................................................... 49
Figure 8. Inhibition of the TGF-β type I receptor alleviates ATP1B1 gene repression by TGF-β. ................................................................. 50
Figure 9. Optimization of siRNA knock-down of transcription factors involved in TGF-β signaling. ................................................................. 51
Figure 10. Regulation of the ATP1B1 gene by TGF-β signaling-associated transcription factors. ................................................................. 52
Figure 11. The ATP1B1 promoter analysis in A549 cells treated with TGF-β. ................................................................. 53
Figure 12. Activity of the ATP1B1 gene and promoter is regulated by DNA methylation. ................................................................. 54
Figure 13. Class I histone deacetylases regulate ATP1B1 gene expression and promoter activity. ................................................................. 55
Figure 14. A particular role for histone deacetylase 2 in the regulation of ATP1B1 gene repression. ................................................................. 56
Figure 15. Histone deacetylase 2 occupancy of the ATP1B1 promoter. ............. 58
Figure 16. Impact of TGF-β on the phosphorylation status of HDAC2. ............... 59
Figure 17. Regulation of Atp1b1 gene expression in alveolar epithelial type II cells by TGF-β and class I histone deacetylases. .................................... 60
Figure 18. Effect of trichostatin A on \textit{Atp1b1} gene expression and pulmonary edema in the bleomycin model of acute respiratory distress syndrome. .......................................................... 61

Figure 19. Effect of trichostatin A on alveolar-capillary barrier permeability in the bleomycin model of acute respiratory distress syndrome. .......................... 62

Figure 20. The effect of trichostatin A on inflammatory responses in the bleomycin model of acute respiratory distress syndrome. ......................... 63

Figure 21. Model of TGF-\(\beta\)/HDAC2-regulated \textit{ATP1B1} gene repression, decreased Na\(^+\) transport and impaired alveolar fluid clearance in acute respiratory distress syndrome. ..................................................... 70
III. List of tables

Table 1. The clinical characteristics of acute respiratory distress syndrome patients.......................................................... 33

Table 2. List of siRNA oligonucleotides used in knock-down experiments. ................................................................. 36

Table 3. Primers used for gene expression analysis. .......................................................... 40

Table 4. Primary antibodies used in western blot analysis. ........................................... 42

Table 5. Primers used in chromatin immunoprecipitation experiments............... 45
## IV. List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AETI</td>
<td>alveolar epithelial type I</td>
</tr>
<tr>
<td>AETII</td>
<td>alveolar epithelial type II</td>
</tr>
<tr>
<td>AFC</td>
<td>alveolar fluid clearance</td>
</tr>
<tr>
<td>ALK</td>
<td>activin receptor-like kinase</td>
</tr>
<tr>
<td>ANF</td>
<td>atrial natriuretic factor</td>
</tr>
<tr>
<td>APACHE</td>
<td>acute physiology and chronic health evaluation</td>
</tr>
<tr>
<td>APS</td>
<td>ammonium persulfate</td>
</tr>
<tr>
<td>ARDS</td>
<td>acute respiratory distress syndrome</td>
</tr>
<tr>
<td>ATF</td>
<td>activating transcription factor</td>
</tr>
<tr>
<td>ATP</td>
<td>adenosine triphosphate</td>
</tr>
<tr>
<td>5-Aza-2′-dC</td>
<td>5-Aza-2′deoxycytidine</td>
</tr>
<tr>
<td>BAL</td>
<td>broncho-alveolar lavage</td>
</tr>
<tr>
<td>bp</td>
<td>base pair(s)</td>
</tr>
<tr>
<td>bZIP</td>
<td>basic leucine zipper</td>
</tr>
<tr>
<td>cAMP</td>
<td>cyclic adenosine monophosphate</td>
</tr>
<tr>
<td>CBP</td>
<td>CREB binding protein</td>
</tr>
<tr>
<td>ChIP</td>
<td>chromatin immunoprecipitation</td>
</tr>
<tr>
<td>CFTR</td>
<td>cystic fibrosis transmembrane conductance regulator</td>
</tr>
<tr>
<td>COL1A2</td>
<td>alpha-2 type I collagen</td>
</tr>
<tr>
<td>CtBP</td>
<td>C-terminal binding protein</td>
</tr>
<tr>
<td>DNA-BP</td>
<td>DNA-binding protein</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified Eagle’s medium</td>
</tr>
<tr>
<td>DSP</td>
<td>3,3′-Dithiodipropionic acid di(N-hydroxysuccinimide ester)</td>
</tr>
<tr>
<td>DTT</td>
<td>dithiothreitol</td>
</tr>
<tr>
<td>EDTA</td>
<td>ethylene dinitril o-N,N,N',N'-tetraacetic acid</td>
</tr>
<tr>
<td>EGF</td>
<td>epidermal growth factor</td>
</tr>
<tr>
<td>EGTA</td>
<td>ethylene glycol-bis (2-aminoethylether)- \ -N,N',N'-tetraacetic acid</td>
</tr>
<tr>
<td>ENaC</td>
<td>epithelial sodium channel</td>
</tr>
<tr>
<td>EVI-1</td>
<td>ecotropic virus integration site 1 protein homolog</td>
</tr>
<tr>
<td>FCS</td>
<td>fetal calf serum</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>FiO₂</td>
<td>fraction of inspired oxygen</td>
</tr>
<tr>
<td>FoxO</td>
<td>forkhead box protein O</td>
</tr>
<tr>
<td>g</td>
<td>gram(s)</td>
</tr>
<tr>
<td>h</td>
<td>hour(s)</td>
</tr>
<tr>
<td>HAT</td>
<td>histone acetyltransferases</td>
</tr>
<tr>
<td>HDAC</td>
<td>histone deacetylase</td>
</tr>
<tr>
<td>kg</td>
<td>kilogram(s)</td>
</tr>
<tr>
<td>KGF</td>
<td>keratinocyte growth factor</td>
</tr>
<tr>
<td>LB-medium</td>
<td>Luria-Bertani medium</td>
</tr>
<tr>
<td>MAD</td>
<td>mothers against decapentaplegic</td>
</tr>
<tr>
<td>mg</td>
<td>milligram(s)</td>
</tr>
<tr>
<td>MH</td>
<td>Mad homolgy</td>
</tr>
<tr>
<td>min</td>
<td>minute(s)</td>
</tr>
<tr>
<td>ml</td>
<td>milliliter(s)</td>
</tr>
<tr>
<td>mM</td>
<td>millimolar</td>
</tr>
<tr>
<td>mmHg</td>
<td>millimeter mercury</td>
</tr>
<tr>
<td>mV</td>
<td>millivolt(s)</td>
</tr>
<tr>
<td>Na,K-ATPase</td>
<td>sodium/potassium-exchanging ATPase</td>
</tr>
<tr>
<td>N-CoR</td>
<td>nuclear receptor co-repressor 1</td>
</tr>
<tr>
<td>ng</td>
<td>nanogram(s)</td>
</tr>
<tr>
<td>nM</td>
<td>nanomolar</td>
</tr>
<tr>
<td>nm</td>
<td>nanometer(s)</td>
</tr>
<tr>
<td>PaO₂</td>
<td>partial pressure of oxygen in arterial blood</td>
</tr>
<tr>
<td>PBS</td>
<td>phosphate buffered saline</td>
</tr>
<tr>
<td>PCAF</td>
<td>p300/CBP-associated factor</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>Pol II</td>
<td>RNA polymerase II</td>
</tr>
<tr>
<td>qPCR</td>
<td>quantitative PCR</td>
</tr>
<tr>
<td>rpm</td>
<td>revolutions per minute</td>
</tr>
<tr>
<td>R-SMAD</td>
<td>receptor SMAD</td>
</tr>
<tr>
<td>RT</td>
<td>room temperature</td>
</tr>
<tr>
<td>RUNX2</td>
<td>Runt-related transcription factor 2</td>
</tr>
<tr>
<td>s</td>
<td>second(s)</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>SDS</td>
<td>sodium dodecyl sulfate</td>
</tr>
<tr>
<td>SEM</td>
<td>standard error of the mean</td>
</tr>
<tr>
<td>SKI</td>
<td>Sloan-Kettering institute</td>
</tr>
<tr>
<td>SnoN</td>
<td>Ski-related novel protein N</td>
</tr>
<tr>
<td>Sp1</td>
<td>specificity protein 1</td>
</tr>
<tr>
<td>SWI/SNF</td>
<td>switch/sucrose nonfermentable</td>
</tr>
<tr>
<td>TBRI</td>
<td>TGF-β receptor type I</td>
</tr>
<tr>
<td>TBRII</td>
<td>TGF-β receptor type II</td>
</tr>
<tr>
<td>TEMED</td>
<td>N,N,N',N'-tetramethylethane-1,2-diamine</td>
</tr>
<tr>
<td>TFE3</td>
<td>transcription factor E3</td>
</tr>
<tr>
<td>TFIID</td>
<td>transcription factor II D</td>
</tr>
<tr>
<td>TGF-α</td>
<td>transforming growth factor-α</td>
</tr>
<tr>
<td>TGF-β</td>
<td>transforming growth factor-β</td>
</tr>
<tr>
<td>TGFB2</td>
<td>TGF-β receptor type 2</td>
</tr>
<tr>
<td>TGIF</td>
<td>transforming growth interacting factor</td>
</tr>
<tr>
<td>TSA</td>
<td>trichostatin A</td>
</tr>
<tr>
<td>μg</td>
<td>microgram(s)</td>
</tr>
<tr>
<td>μl</td>
<td>microliter(s)</td>
</tr>
<tr>
<td>μM</td>
<td>micromolar</td>
</tr>
<tr>
<td>μm</td>
<td>micrometer(s)</td>
</tr>
<tr>
<td>YY1</td>
<td>yin-yang 1</td>
</tr>
</tbody>
</table>
1. Introduction

1.1. Acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is a clinical syndrome which develops rapidly and results in respiratory failure. A recently proposed interpretation of ARDS, the Berlin definition, includes a value of the PaO$_2$/FiO$_2$ ratio of below 300 mmHg, acute onset and the presence of bilateral opacities present on chest radiographs consistent with pulmonary edema (Ranieri et al., 2012). The disease is categorized by the degree of hypoxemia: mild (PaO$_2$/FiO$_2$ ratio between 300 and 200 mmHg), moderate (PaO$_2$/FiO$_2$ ratio between 200 and 100 mmHg) or severe (PaO$_2$/FiO$_2$ ratio below 100 mmHg). Patients with ARDS require urgent admission to critical care units for advanced life support and utilize considerable health care resources.

Acute respiratory distress syndrome has multiple etiologies and can develop as a result of direct injury to the lungs, such as after viral or bacterial pneumonia, aspiration of gastric contents, or smoke or toxic gas inhalation. Alternatively, ARDS can occur indirectly during the course of systemic inflammation, such as during sepsis; or after trauma or blood transfusion (Ware and Matthay, 2000). The risk of ARDS development is higher in patients with pneumonia, severe sepsis, and aspiration of gastric contents, hemorrhage or trauma (Matthay and Zemans, 2011). Multi-organ failure is the most common cause of death in patients with ARDS (Lipes et al., 2012). The mortality rate of ARDS is 27-45% and depends on the severity of disease (Ranieri et al., 2012). Mortality risk depends on the nature of the underlying disorder and is higher for patients with sepsis, pneumonia or aspiration (Rubenfeld et al., 2005; Eisner et al., 2001). Additionally, the risk of death is influenced by age and race, since younger patients have lower mortality rates and Afro-Americans or Hispanics have increased risk of death when compared to Caucasians (Rubenfeld et al., 2005; Eisner et al., 2001). Currently, the therapy for ARDS remains limited to lung-protective mechanical ventilation while several pharmacological therapies evaluated have proven to be ineffective.
1.1.1. Pathology of acute respiratory distress syndrome

The alveolar-capillary barrier is the basic functional unit of the lung, formed by adjacent layers of the alveolar epithelium, a basement membrane and the microvascular endothelium. The integrity of this delicate system is crucial for maintaining liquid homeostasis in the lung, leaving the alveolar surface relatively dry and, ultimately, allowing effective gas exchange.

Irrespective of the nature of the primary insult triggering ARDS, specific histopathological characteristics are common to all ARDS pathology. Based on histological evidence, the progression of ARDS can be divided into three phases, with the acute phase being the most immediate, followed first by the proliferative and then the fibrotic stages, which together constitute the chronic phase.

The acute phase persists during the initial seven days after insult to the lung. In the acute phase, the alveolar-capillary barrier is destroyed, which causes permeability and alveolar flooding. In consequence, pulmonary edema develops, which decreases the efficiency of gas exchange, and eventually causes respiratory failure. Cell necrosis, inflammation and fibrotic processes, collectively referred to as diffuse alveolar damage, are routinely observed and are responsible for loss of alveolar-capillary barrier integrity (Ware and Matthay, 2000). The key histopathological features of the acute phase of ARDS are demonstrated in Figure 1.

The majority of patients who survive the acute stage of ARDS enter the proliferative phase, which is characterized by the presence of hyperplastic alveolar epithelial type II (AETII) cells and fibroblasts. The AETII cells migrate along alveolar septa and proliferate in order to reconstitute epithelial integrity (Geiser, 2003). Additionally, fibroblasts deposit extracellular matrix proteins which transform the intra-alveolar space into fibrous tissue and obliterate the alveolar space (Marshall et al., 1998).

The effort of epithelial repair undertaken during the proliferative phase may result in complete restoration of lung function. Nevertheless, proper re-epithelialization is frequently disturbed and can cause progression into the fibrotic phase of ARDS (Ware and Matthay, 2000). In this final stage, the alveolar space is filled with proliferating fibroblasts, abnormal amounts of extracellular matrix and new blood vessels, a characteristic collectively described as fibrosing alveolitis (Ware, 2006).
Figure 1. Comparison of a healthy alveolus to a damaged alveolus in the acute phase of acute respiratory distress syndrome. A healthy alveolus (left-hand side) is characterized by the presence of intact endothelial and epithelial barriers and balanced regulation of the alveolar fluid volume and composition. In the acute respiratory distress syndrome (right-hand side), the integrity of the alveolar-capillary barrier is lost, which promotes accumulation of protein-rich edema fluid in the alveoli (from Ware and Matthay, 2000).

1.1.2. Injury to the alveolar-capillary barrier promotes edema formation and persistence in acute respiratory distress syndrome

Damage to the endothelial and epithelial barriers perturbs fluid balance and leads to alveolar flooding in the acute phase of ARDS (Ware, 2006). The injury to the pulmonary vasculature was documented by Tomashefski et al., who reported substantial ultrastructural lesions in the capillary endothelium in patients with ARDS (Tomashefski et al., 1983). It appears that granulocyte recruitment in the pulmonary microvasculature is responsible for capillary endothelial damage (Looney et al., 2006). Activated,
degranulating neutrophils are a source of proteases, proinflammatory cytokines, procoagulants and reactive oxygen species, all of which can injure microvascular endothelial cells and cause extravasation of protein-rich fluid (Matthay and Zemans, 2011). However, despite that endothelial dysfunction is evident in ARDS, increased vascular permeability is insufficient to facilitate edema formation in presence of a morphologically and functionally intact alveolar epithelium, suggesting that injury to the endothelium alone is incapable to cause ARDS (Wiener-Kronish et al., 1991).

The intensity of the injury to the epithelium and edema level correlates with the severity of the ARDS and is associated with poor outcome (Ware and Matthey, 2001, Matthay and Wiener-Kronish, 1990). Destruction of the epithelial wall results in functional impairment of lung function on multiple levels. Since alveolar epithelial cells are exceptionally tightly connected, the epithelial barrier is much less permeable compared to the microvascular endothelial barrier. Therefore, loss of epithelial wall integrity has more severe consequences than the destruction of the endothelial layer, and contributes to the accumulation of protein-rich edema fluid in the alveoli to a high degree (Wiener-Kronish et al., 1991). An ultrastructural study of epithelial injury in ARDS revealed cell vacuolization, cytoplasmic swelling, focal detachment from the basement membrane, and necrosis (Ware, 2006, Tomashefski, 2000). Eradication of alveolar epithelial type I (AETI) cells results in a reduction of gas exchange surface area and delivers a major initial blow to epithelial layer integrity, allowing the influx of edema fluid into the alveolar space (Ware and Matthey, 2000). On the contrary, AETII cells seem to be more resistant to the initial insult. Additionally, AETII cells proliferate and differentiate into AETI cells and are critical for re-epithelization and repair of the alveolar epithelium after injury (Geiser, 2003).

Apart from increased fluid permeability, the destruction of the epithelial layer has another fundamental consequence in the form of perturbed lung liquid reabsorption in ARDS (Modelska et al., 1999, Laffon et al., 1999). The major force driving water movement in the lung is Na⁺ transport from the alveolar lumen across the epithelium via the apically-located epithelial sodium channel (ENaC) and the basolaterally-located sodium/potassium-exchanging ATPase (Na,K-ATPase) into the interstitium (Matthay et al., 2002). The polarized distribution of Na⁺ transporters in the plasma membranes of alveolar epithelial cells is essential for vectorial Na⁺ transport and formation of an osmotic gradient, which is followed by isoosmotic water reabsorption from the alveoli in the process of alveolar fluid clearance (AFC) (Matthay et al., 2002).
1.2. Alveolar fluid clearance

Both AETI and AETII cells express elements of the Na\(^+\) transporting machinery and are able to perform Na\(^+\) ion transport and drive AFC (Matthay and Zimmerman, 2005). The function of ENaC is to passively conduct Na\(^+\) ions from alveolar space into alveolar epithelial cells (Guidot et al., 2006). Four types of subunits, α-ENaC, β-ENaC, γ-ENaC and δ-ENaC were found in human lung epithelial cells (Zhao et al., 2012, Berthiaume and Matthay, 2007). The role of ENaC is important for lung fluid homeostasis, since inhibition of ENaC by amiloride partially prevents Na\(^+\) uptake by AETI cells in vitro and inhibits basal AFC in human and other mammalian lungs (Matthay et al., 2002). Furthermore, deletion or diminished expression of the mouse α-ENaC gene results in pulmonary edema and causes respiratory distress syndrome (Egli et al., 2004, Matthay et al., 2002). The activity of ENaC can be directly modulated by cAMP, or indirectly, via regulation of gene expression, by glucocorticoids and catecholamines (Berthiaume and Matthay, 2007). Additionally, the cystic fibrosis transmembrane conductance regulator (CFTR), a Cl\(^-\) ion channel expressed in AETI and AETII cells, has been also found to be involved in the AFC process (Berthiaume and Matthay, 2007).

The Na,K-ATPase generates an electrochemical gradient across the basolateral membrane of AETI and AETII cells by actively pumping K\(^+\) ions into the cell, and extruding Na\(^+\) ions into the interstitium. An analysis of the Na,K-ATPase pump structure revealed the presence of three types of subunits: ATP1A, ATP1B and FXYD (also known as α, β and γ proteins, respectively). The structure of Na,K-ATPase is illustrated in Figure 2. The ATP1A and ATP1B subunits form the core of the Na,K-ATPase, and are indispensable for pump function (Geering, 2008). The ATP1A subunit, which has four isoforms (ATP1A1-ATP1A4), is the catalytic unit that transports Na\(^+\) and K\(^+\) ions and hydrolyzes ATP, which is required for ion-conducting activity. Since ATP1A is unable to localize itself into cell membrane, the presence of the ATP1B subunit (isoforms ATP1B1-ATP1B3) is critically required for assembly, membrane insertion and stability of the Na,K-ATPase complex, and only the ATP1A-ATP1B heterodimer can perform pump function (Geering, 2006). Moreover, Barquin and colleagues have suggested that ATP1B1 subunit abundance is the rate limiting factor for Na,K-ATPase assembly and activity in isolated rat AETII cells and the lung (Barquin et al., 1997).
Figure 2. Architecture of the Na,K-ATPase. The X-ray crystal structure at 3.5 Å resolution of the porcine renal Na,K-ATPase consisting of ATP1A (blue), ATP1B (brown) and FXYD (red) subunits (adapted from Morth et al., 2007).

The activity of the Na,K-ATPase is carefully controlled, and involves direct and indirect mechanisms. Direct mechanisms include covalent modifications and allosteric structure fine-tuning. The indirect system of regulation includes trafficking of the Na,K-ATPase between plasma membrane and endosomal pools, and synthesis/degradation rate adjustment (Matthay et al., 2002). Moreover, modulation of the expression of Na,K-ATPase-encoding genes by hyperoxia or β-adrenergic, glucocorticoid/mineralocorticoid and thyroid systems has also been reported (Berthiaume and Matthay, 2007, Matthay et al., 2002). Complex regulation of pump-encoding gene transcription and mRNA translation have a persistent effect on Na,K-ATPase activity, while dopaminergic and adrenergic stimulation rapidly induce Na,K-ATPase phosphorylation and trafficking to the cell membrane (Matthay et al., 2002). Finally, studies with the Na,K-ATPase inhibitor ouabain in AETII cells, in
resected human lungs and in live animals revealed that the Na,K-ATPase is essential for Na\(^+\) transport and AFC in intact healthy lungs as well as after injury (Berthiaume and Matthay, 2007, Matthay et al., 2002).

1.2.1. Alveolar fluid clearance is impaired in acute respiratory distress syndrome

A damaged and permeable alveolar epithelium allows rapid water accumulation and edema formation which cannot be resolved because of impaired AFC processes caused by defective ion transport (Sartori and Matthay, 2002). A number of factors have been shown to perturb transepithelial ion transport and, consequently, decrease AFC (highlighted in Figure 3). After lung injury, Na\(^+\) transport via ENaC and the Na,K-ATPase can be directly reduced by secondary inflammatory mediators including reactive oxygen and nitrogen species (Lecuona et al., 2007, Morty et al., 2007, Matthay et al., 2002). Hypoxia, which develops during ARDS, reduces Na\(^+\) transport in AETII cells and impairs the AFC process (Sartori and Matthay, 2002). Various cytokines that are involved in the pathogenesis of ARDS, including tumor necrosis factor-\(\alpha\), interleukin-1\(\beta\) and transforming growth factor (TGF)-\(\beta\), and infectious agents, including Pseudomonas or influenza virus; inhibit Na\(^+\) transport and prevent AFC (Morty et al., 2007, Frank et al., 2003, Matthy et al., 2002, Evans et al., 1998). Additionally, active Na\(^+\) transport and subsequent AFC are inhibited by Na,K-ATPase endocytosis early in sepsis-induced lung injury (Berger et al., 2011). Lecuona and colleagues described a reduction in Na,K-ATPase function in AETII cells in a rat model of ventilator-induced ARDS. Since AFC in these animals was also reduced, this study highlights the importance of proper patient ventilation in the intensive care unit, which must not further hamper already weakened Na\(^+\) transport and edema fluid resolution mechanisms (Lecuona et al., 1999). Despite the strong evidence for decreased transepithelial Na\(^+\) transport in various models of ARDS, it is important to note that mild lung injury can have the opposite effect and improve Na\(^+\) transport and AFC (Matthay et al., 2002). Increased Na\(^+\) uptake after mild lung injury may serve as a natural mechanism preventing alveolar flooding and may offer some protection against lung injury.
1.2.2. Upregulation of alveolar fluid clearance can improve acute respiratory distress syndrome

Several clinical studies demonstrate that patients with enhanced AFC display improvement in ARDS and increased survival in contrast to those without efficient AFC function (Ware and Matthay, 2001, Matthay and Wiener-Kronish, 1990, Ware et al., 1999). Therefore, it is reasonable to preserve and, if possible, to increase AFC in the lungs of ARDS patients (Berthiaume and Matthay, 2007, Sartori and Matthay, 2002). A number of experimental studies have demonstrated the positive impact of Na⁺ transport reactivation on increased AFC in animal models of ARDS (reviewed by Morty et al., 2007 and Sartori and Matthay, 2002; summarized in Figure 4). Dopamine and β₂-agonists have been reported to stimulate AFC in multiple experimental models of ARDS by exocytosis of Na,K-ATPase from intracellular pools to the basolateral cell membrane of alveolar epithelial cells. The positive effect of β₂-agonists on pulmonary edema resolution in humans has been reported by Perkins and colleagues, who observed decreased lung water in a randomized placebo-controlled clinical phase II trial of 40 ARDS patients receiving intravenous salbutamol (Perkins et al., 2006). However, despite these encouraging results, large, randomized and placebo-controlled clinical trial
on 282 patients with ARDS did not demonstrate increased number of ventilator-free days in the group receiving aerolized albuterol, while another study of intravenous treatment with salbutamol revealed that use of β2-agonists could even worsen outcome (Gao Smith et al., 2012, ARDS Network, 2011).

Several groups have reported that animals or isolated lungs pretreated with keratinocyte growth factor (KGF) or KGF-expressing virus particles displayed enhanced Na⁺ transport and AFC, and did not develop edema in response to injury (Baba et al., 2007, Morty et al., 2007). It has been demonstrated that transepithelial ion transport is increased in KGF-treated rat AETII cells, which could be attributed to upregulation of Atp1a1 gene expression and increased Atp1a1 and Atp1b1 protein abundance in these cells (Borok et al., 1998). Similar to KGF, transforming growth factor (TGF)-α also has the capability of improving AFC, albeit through increasing Na⁺ uptake as opposed to KGF-induced Na,K-ATPase expression (Folkesson et al., 1996). Additionally, TGF-α-overexpressing mice demonstrate reduced lung edema and decreased mortality in nickel-induced lung injury (Hardie et al., 2002).

**Figure 4. Strategies for improving Na⁺ transport and edema resolution in acute respiratory distress syndrome.** CFTR, cystic fibrosis transmembrane conductance regulator; EGF, epidermal growth factor (from Morty et al., 2007).
Contrary to routes of indirect stimulation of Na\(^+\) transport, gene therapy by the delivery of Na,K-ATPase subunit-encoding DNA directly augments Na\(^+\) transporting machinery and improves AFC and edema resolution (Adir et al., 2003, Azzam et al., 2002, Stern et al., 2000, Factor et al., 2000, Factor et al., 1998). Interestingly, these experiments proved that increased AFC in ARDS apparently relies on the ATP1B1 subunit (responsible for Na,K-ATPase membrane stability), but not on the ATP1A1 subunit (serving as Na,K-ATPase catalytic centre).

As mentioned above, indirect stimulation of the Na,K-ATPase by TGF-\(\alpha\) and KGF, or direct pump augmentation by ATP1B1 subunit overexpression, improved Na\(^+\) transport only in a pretreatment setting, thus limiting the therapeutic potential of these approaches in established ARDS. Moreover, lung protective ventilation with low tidal volumes, the only valid option for ARDS patients, is still not widely employed in intensive care units (Lipes et al., 2012, ARDS Network, 2000). This fact, together with the recently reported ineffectiveness of \(\beta_2\)-agonist therapy, limits possible treatment options for ARDS. The lack of effective treatment options, the overall high mortality and the significant economic burden of ARDS stress the need for the development of new therapeutic strategies. Advances in our understanding of the pathogenesis of this disorder have identified several molecular signaling pathways, including the TGF-\(\beta\) network, which could be potential targets for the future therapy of ARDS.

1.3. Transforming growth factor-\(\beta\) signaling

The members of the TGF-\(\beta\) superfamily of peptide growth factors are evolutionarily conserved amongst vertebrates and regulate embryonic development and organogenesis, wound repair, immune response and hematopoiesis, and control various cell functions (Goumans and Mummery, 2000). The deregulation of TGF-\(\beta\) signaling has been implicated in several lung diseases, including cancer, pulmonary fibrosis, pulmonary arterial hypertension and ARDS (Santibañez et al., 2011, Eickelberg and Morty, 2007, Dhainaut et al., 2003). In alveolar epithelial cells, TGF-\(\beta\) inhibits proliferation, induces apoptosis and epithelial-to-mesenchymal transition (Yamasaki et al., 2008, Willis and Borok, 2007, Zhang et al., 2004,). Secreted in an inactive form and subsequently deposited into extracellular matrix, TGF-\(\beta\) is coupled to latency-associated peptide and latent TGF-\(\beta\)-binding proteins. The availability of TGF-\(\beta\) is tightly controlled and various factors, including proteases (plasmin, matrix
metalloproteinases), reactive oxygen species, integrins and shear forces, have been reported to activate and release the deposited TGF-β (Munger and Sheppard, 2011). The activated TGF-β can be recognized by the cell surface-expressed TGF-β receptor type I (TBRI) and type II (TBRII). The TBRI receptors include activin receptor-like kinase (ALK)1 and ALK5, while TGF-β receptor 2 (TGFBR2) represents the TBRII family. Additionally, auxiliary type III receptors: betaglycan and endoglin, enhance TGF-β signaling by presenting ligand to the TBRI and TBRII complexes (Santibañez et al., 2011). The serine/threonine kinases TBRI/TBRII form the core of the receptor, and upon ligand binding undergo heterodimerization and conformational changes in a series of phosphorylation events (Massagué and Chen, 2000). Initially, recognition of the ligand by TBRII triggers phosphorylation of TBRI followed by reorganization of receptor structure and results in tight association of both molecules. In the subsequent step, TBRI catalyzes the phosphorylation and activation of SMAD proteins (homologs of the Drosophila protein mothers against decapentaplegic (MAD) and Caenorhabditis elegans protein SMA) which are docked to the receptor complex on cytoplasmatic side (Massagué and Gomis, 2006).

1.3.1. Function of SMAD proteins in the transcriptional regulation of gene expression

In the canonical TGF-β pathway (schematically depicted in Figure 5), activated SMAD2 and SMAD3 proteins form complexes with SMAD4, translocate into the nucleus and act as transcription factors (Massagué and Chen, 2000). Also called receptor SMADs (R-SMADs), SMAD2 and SMAD3 share similar protein structures, with the presence of highly conserved MH1 and MH2 (where MH is Mad homology) domains on the N-terminus and the C-terminus, respectively, separated by linker region. The MH1 domain is responsible for DNA binding while MH2 domain express transcriptional regulation activity and facilitates protein-protein interactions (ten Dijke and Hill, 2004, Ross and Hill, 2008).

Heterodimers consisting R-SMADs and SMAD4 form multiprotein complexes with various transcription factors and transcription co-factors in order to execute the primary function of the TGF-β/SMAD signaling which is gene expression regulation (Massagué and Chen, 2000).
The intrinsic DNA-binding capability of SMADs is relatively weak and it seems that these proteins do not exhibit strict DNA sequence specificity by binding 5′-AGAC-3′ sequences as well as GC-rich DNA regions, while the most abundant SMAD2 isoform completely lacks DNA-binding activity (Shi et al., 1998, Zawel et al., 1998, Kim et al., 1997). To overcome these drawbacks, SMAD proteins frequently recruit other transcription factors to specifically target and regulate genes downstream of TGF-β signaling. Additionally, as the TGF-β pathway regulates the expression of more than 1300 genes in the human AETII cell-like A549 cell-line alone, these additional transcription factors are necessary to aid the structurally similar SMAD proteins in precise, dynamic and cell-specific gene regulation (Ranganathan et al., 2007, Keating et al., 2006).
1.3.2. SMAD-associated transcription factors and transcription co-factors

A significant number of transcription factors interact and regulate gene expression in concert with SMADs (Feng and Derynck, 2005). The character of the partner transcription factor governs the response to TGF-β and may result in the upregulation or downregulation of target gene expression. The DNA-binding transcription factors known to form transcription-activating complexes with SMADs include forkhead box protein O (FoxO) proteins, specificity protein 1 (Sp1), transcription factor E3 (TFE3) and basic leucine zipper (bZIP) family proteins c-Jun, JunB or activating transcription factor (ATF) 2 and ATF3 (Feng and Derynck, 2005, Seoane et al., 2004, Feng et al., 2000, Hua et al., 1999). Additionally, TGF-β signaling synergizes with NF-kappaB, Notch and p53 pathways (Blokzijl et al., 2003, Cordenonsi et al., 2003, López-Rovira et al., 2000). The primary role of SMADs and partner transcription factors is recognition and binding to specific DNA sequences in the TGF-β target gene promoter. However, the capacity of SMAD proteins to induce transcription is limited, and additional factors, named transcriptional co-activators, are required. The transcriptional co-activators (such as switch/sucrose nonfermentable (SWI/SNF) and ARC105 proteins) lack intrinsic DNA-binding domains but have the ability to modify chromatin structure and stabilize transcriptional machinery, thus significantly amplifying the rate of transcription (Ross et al., 2006, Massagué et al., 2005, Kato et al., 2002).

In contrast to driving gene expression, the mechanisms of TGF-β-dependent gene repression are much less understood, and a number of SMAD-associated transcription factors can play a dual role, acting as a activators as well as repressors, including the already-mentioned p53 (Cordenonsi et al., 2003, Wilkinson et al., 2005). Up to now, several mechanisms of TGF-β/SMAD-regulated gene repression have been described. The gene-activating function of SMADs can be directly suppressed by binding ecotropic virus integration site 1 protein homolog (EVI-1), yin-yang 1 (YY1), Sloan-Kettering institute (SKI) and Ski-related novel protein N (SnoN) transcriptional repressors (Kurisaki et al., 2003, Alliston et al., 2005). Conversely, SMADs may abolish the function of transcriptional activators, as in the case of the interaction between SMAD3 and Runt-related transcription factor 2 (RUNX2) (Alliston et al., 2001). Finally, SMADs may form complexes with specialized transcriptional repressors E2F4
and E2F5 to inhibit gene expression (Chen et al., 2002). Several other transcriptional regulators including transforming growth interacting factor (TGIF), SKI and SNON, can associate with SMADs and may repress the gene expression in a similar fashion (Liberati et al., 2001, Stegmüller et al., 2008, Mizuide et al., 2003, Stroschein et al., 1999, Wotton et al., 1999). Likewise, transcription factor ATF3 associates with SMAD3 in TGF-β-treated epithelial cells and represses the ID1 gene (Kang et al., 2003). Finally, Vincent and colleagues reported that TGF-β induces the interaction of SMAD3 and SMAD4 with the transcriptional repressor SNAI1, leading to repression of CAR, OCCLUDIN, CLAUDIN-3 and E-CADHERIN genes and ultimately epithelial-to-mesenchymal transition (Vincent et al., 2009).

1.3.3. Epigenetic mechanisms in TGF-β-dependent gene regulation

While binding DNA, SMADs and associated transcription factors recruit transcriptional co-activators or co-repressors to finally execute a gene activation or repression program. These two opposite processes may involve epigenetic mechanisms, which modify the accessibility of the eukaryotic transcription machinery by methylating DNA, or by covalently modifying histone proteins. The balance of cytosine methylation in 5'-CG-3' dinucleotides by DNA methyltransferases and DNA glycosylases is an important mechanism of gene regulation during development. Aberrant DNA methylation patterns have been identified in several diseases including cancer (Wu and Grunstein, 2000). Histone proteins form the core of the nucleosome, the basic structural unit of chromatin, and are responsible for chromatin compacting. Histones are subjected to extensive posttranslational modifications, including lysine acetylation, lysine and arginine methylation, and serine, threonine or tyrosine phosphorylation (Wu and Grunstein, 2000). These covalent modifications alter the histone-DNA interaction and may allow transcription by opening the chromatin structure or facilitate the formation of a closed state of chromatin, which is inaccessible to the transcription machinery. Lysine acetylation plays an important role during the regulation of gene expression, and this modification is characteristic of genes undergoing active transcription. Two types of transcription co-factors control lysine acetylation and, therefore, gene expression:
histone acetyltransferase (HAT) activates while histone deacetylase (HDAC) represses transcription (Wu and Grunstein, 2000).

TGF-β signaling utilizes the function of DNA glycosylases, HAT and HDAC proteins to regulate gene expression. Thillainadesan and colleagues demonstrated that TGF-β induces the interaction between SMAD2-SMAD3 and thymine DNA glycosylase, which conducts active DNA demethylation, activating the p15\textsuperscript{ink4b} gene (Thillainadesan et al., 2012). Several SMAD-interacting proteins exhibit endogenous HAT activity. A study by Kahata and colleagues revealed that a histone H3 acetyltransferase, GCN5, together with SMAD3, localize to the SERPINE1 gene promoter and activate transcription (Kahata et al., 2004). Moreover, SMAD3, together with SMAD2, forms a complex with another HAT enzyme, p300/CBP-associated factor (PCAF), which amplifies the transcription-inducing properties of SMADs (Kahata et al., 2004, Itoh et al., 2000). Undoubtedly, the nature of the interaction between p300/CBP and SMAD2, SMAD3 and SMAD4 is the most well documented among all SMAD-interacting HATs (Nishihara et al., 1998, Pouponnot et al., 1998). Several TGF-β target genes have been identified to be activated by assembled p300/CBP-SMAD3 or p300/CBP-SMAD4 complexes, including SERPINE1, p15 and the α-2 type I collagen-encoding gene (COL1A2) (Ghosh et al., 2000, Shen et al., 1998, Feng et al., 1998).

The HDAC family forms a distinct group of co-repressors operated by TGF-β signaling to downregulate gene expression. Based on homology and cellular localization, this family of zinc-dependent hydrolases is separated into four classes: class I (HDAC1, HDAC2, HDAC3 and HDAC8), class IIa (HDAC4, HDAC5, HDAC7 and HDAC9), class IIb (HDAC6 and HDAC10) and class IV (HDAC11) (Bieliauskas and Pflum, 2008). It has been reported that SMAD3 and SMAD4 directly interact with HDAC1, and protein complexes containing SMADs exhibit histone deacetylation activity (Liberati et al., 2001). The interaction of SMAD3 with HDAC4 and HDAC5 results in repression of the osteocalcin gene (Kang et al., 2005). The recruitment of HDAC proteins by SMADs may also be indirect, where other transcription factors serve as adaptors. Evidence provided by Wotton and colleagues demonstrated that TGIF competes with the p300/CBP activator for binding SMAD2, and recruits HDAC1 to the SMAD2-TGIF complex (Wotton et al., 1999). Additionally, SKI and SNON co-repressors seem to recruit HDAC proteins to SMAD-containing complexes. Akiyoshi et al. demonstrated that SKI abolishes interaction between SMAD3 and p300 HAT and
recruits HDAC1 to SMAD3 in TGF-β-stimulated cells (Akiyoshi et al., 1999). While SKI-mediated sequestration of HDAC seems to actively antagonize TGF-β/SMAD-mediated induction of at least some genes, SNON maintains the TGF-β target genes in an inactive state under basal conditions. It has been speculated that SNON may recruit HDACs to the SMAD2/SMAD4 complexes via the nuclear receptor co-repressor 1 (N-CoR) adaptor protein (Stroschein et al., 1999). The human homolog of Drosophila gene Sna, SNAI1, represents another transcription factor known to mediate TGF-β signaling, which has also been found to interact with HDACs. Peinado and collaborators described a mechanism where SNAI1, together with HDAC1 and HDAC2, repress E-Cadherin gene (Peinado et al., 2004).

1.4. The role of TGF-β signaling in acute respiratory distress syndrome

In the lung, TGF-β is secreted by alveolar macrophages, alveolar epithelial cells and fibroblasts, and is involved in normal lung tissue repair as well as being a critical mediator of pulmonary fibrosis (Khalil et al., 1996, Sime et al., 1997). Additionally, several lines of evidence have implicated TGF-β in processes preceding the development of pulmonary fibrosis. Increased levels of TGF-β have been found in broncho-alveolar lavage (BAL) fluid from ARDS patients and lower levels of TGF-β are related to a lower severity of ARDS (Fahy et al., 2003, Budinger et al., 2005). In ARDS, TGF-β is expressed by fibroblasts, alveolar macrophages and alveolar epithelial cells adjacent to fibrotic foci (Fahy et al., 2003).

The increased levels of TGF-β in BAL fluids from ARDS patients robustly stimulated the activity of the procollagen gene promoter, a fibroproliferative marker and predictor of the severity of ARDS, which could indicate that TGF-β may execute gene regulation programs shortly after the onset of lung injury (Budinger et al., 2005). An analysis of gene expression dynamics in bleomycin- or nickel-induced ARDS models identified a group of TGF-β-target genes involved in the inflammatory response and extracellular matrix deposition to be differentially regulated shortly after the onset of injury. Additionally, the expression of the β-ENaC subunit- and Na,K-ATPase Atp1b1 subunit-encoding genes was decreased, suggesting that disruption of the AFC machinery may occur very early during ARDS progression (Wesselkamper et al., 2005). In vitro experiments confirmed that TGF-β boosts vascular endothelial cell permeability, and
decreases transepithelial electrical resistance of primary AETII cells, suggesting a key role for TGF-β signaling in the regulation of ion transport and pulmonary edema formation and persistence in ARDS (Pittet et al., 2001, Hurst et al., 1999). It appears that TGF-β directly targets ENaC channels to perturb ion transport in the lung, as TGF-β treatment decreases α-ENaC subunit-encoding gene expression, and inhibits amiloride-sensitive Na⁺ uptake and fluid transport across the alveolar epithelium in vitro and in vivo (Frank et al., 2003). In contrast, low doses of TGF-β not only preserve α-ENaC subunit encoding gene expression but also increase the abundance of Na,K-ATPase subunits ATP1A1 and ATP1B1, and stimulate active ion transport across AETII cell monolayers (Willis et al., 2003). It is important to note, however, that this effect was accompanied by reduced transepithelial resistance and perturbed formation of tight epithelial monolayers (Willis et al., 2003). Collectively, these observations imply that TGF-β may have a biphasic effect on the epithelial barrier, by stimulating active ion transport at low doses, and disrupting barrier integrity at higher concentrations.

Additional evidence confirming the involvement of TGF-β in ARDS comes from studies where investigators employed tools to block the TGF-β signaling in animal models of ARDS. Pittet and colleagues have suggested a key role of integrin αvβ6 in the local activation of latent TGF-β, since αvβ6−/− mice are protected from edema formation, hemorrhage and accumulation of proteinaceous material in the alveoli after bleomycin or endotoxin instillation (Pittet et al., 2001). Additionally, scavenging active TGF-β with a soluble chimeric TGF-β type II receptor decreases protein levels in BAL fluid and epithelial permeability to protein in nickel- and bleomycin-induced lung injury (Pittet et al., 2001, Wesselkamper et al., 2005). However, it is important to note that blocking TGF-β signaling does not affect neutrophil recruitment to the alveoli, suggesting that neutrophil-mediated inflammatory responses are not modulated by TGF-β (Wesselkamper et al., 2005).

Despite the evident involvement of TGF-β in ARDS pathogenesis, functional TGF-β signaling is an important mechanism ensuring organ homeostasis and lung recovery from ARDS. Both inflammation and extracellular matrix modulation are engaged in the tissue repair processes, and are dynamically regulated by TGF-β. In this way, locally deposited TGF-β may be activated by proximal damage and, in response, coordinate securing the perimeter around injured lung tissue and limit the potentially dangerous uncontrolled spread of inflammation (Sheppard, 2006).
2. **Hypothesis and aims of the study**

The formation and persistence of pulmonary edema is a hallmark of ARDS (Ranieri et al., 2012). The resolution of pulmonary edema in ARDS is inhibited by impaired Na$^+$ transport and insufficient AFC (Sartori and Matthy, 2002). The basolaterally-located Na,K-ATPase establishes an electrochemical gradient across the epithelium which drives osmotic water reabsorption from the alveoli (Matthay et al., 2002). The expression of genes encoding the essential Na,K-ATPase subunit, Atp1b1, has been reported to be reduced in a nickel-induced ARDS model (Wesselkamper et al., 2005). Furthermore, TGF-β has been recognized as a key mediator of ARDS pathogenesis, and is known to perturb Na$^+$ transport and AFC (Wesselkamper et al., 2005, Pittet et al., 2001, Massagué and Chen, 2000). Therefore, it has been hypothesized here that: (i) the expression of Na,K-ATPase encoding genes is deregulated by TGF-β in ARDS patients and in bleomycin model of ARDS in mice; and (ii) restoration of normal expression of genes encoding Na,K-ATPase subunits may improve AFC in the bleomycin model of ARDS.

In detail, the specific aims of this study were:

1. to investigate whether parallel trends in the expression of the Na,K-ATPase subunit-encoding genes exist in the lungs from ARDS patients and in alveolar epithelial cells treated with TGF-β;
2. to elucidate the mechanism of TGF-β-induced regulation of Na,K-ATPase subunit-encoding genes simultaneously regulated in ARDS patients and TGF-β-treated cells;
3. to target and disrupt the gene expression regulatory machinery employed by TGF-β signaling to regulate the Na,K-ATPase subunit-encoding gene expression;
4. to test whether recuperation of the Na,K-ATPase subunit-encoding gene expression may improve alveolar edema status in the bleomycin model of ARDS.
3. **Materials and methods**

3.1. **Materials**

3.1.1. **Technical equipment**

Autoclave; Systec, Germany
Bacteria culture incubator; Heraeus, Germany
Cell culture incubator HERAcell 150i; Thermo Scientific, USA
Cell culture sterile working bench; Thermo Scientific, USA
Cell strainers: 100, 40 μm; BD Falcon™, USA
Centro LB 960 microplate luminometer; Berthold, Germany
Costar® 12 mm Snapwell™ insert; Corning, USA
Countess® cell counter; Invitrogen, UK
Developing machine X Omat 2000; Kodak, USA
Dynal® MX2 sample mixer; Applied Biosystems, USA
Electrophoresis chambers; Bio-Rad, USA
Espresso personal microcentrifuge; VWR, USA
Gel blotting paper; Bioscience, Germany
InoLab® pH meter; WTW, Germany
Isoplate™ B&W 96-well plate; PerkinElmer, USA
Light microscope; Leica, Germany
MicroAmp® 8-tube strip; Applied Biosystems, USA
MicroAmp® FAST 96-well reaction plate; Applied Biosystems, USA
Microcentrifuge tubes: 0.5, 1.5, 2 ml; Eppendorf, Germany
Microsprayer™; Penn-Century Inc, USA
Mini shaker; VWR, USA
Mini Trans-Blot® western blot chambers; Bio-Rad, USA
Mini-Protean® 3 Cell; Bio-Rad, USA
Minispin® centrifuge; Eppendorf, Germany
Multifuge 3 S-R centrifuge; Heraeus, Germany
MS-100 thermo shaker; Universal Labortechnik, Germany
NanoDrop® ND 1000; PeqLab, Germany
Nylon net filters 20 μm; Millipore, USA
peqSTAR 96 universal gradient thermocycler; Peqlab, USA
Petri dishes for bacteria; Greiner Bio-One, Germany
Pipetboy; Eppendorf, Germany
Pipetmans: P10, P20, P100, P200, P1000; Gilson, France
Pipetman filter tips: 10, 20, 100, 200 and 1000 μl; Greiner Bio-One, Germany
Precellys® 24 homogenizer; Bertin Technologies, France
Refrigerated microcentrifuge CT15RE; VWR, USA
Serological pipettes: 2, 5, 10, 25, 50 ml; Falcon, USA
Sonopuls HD 2070 ultrasonic homogenizer; Bandelin, Germany
StepOnePlus™ Real-Time PCR system; Applied Biosystems, USA
Test tubes: 15, 50 ml; Greiner Bio-One, Germany
Tissue culture dish 100 mm; Greiner Bio-One, Germany
Tissue culture flask 250 ml; Greiner Bio-One, Germany
Tissue culture plates: 6-, 12-, 48- and 96-well; Greiner Bio-One, Germany
Tissue culture plates: 12-well; Greiner Bio-One, Germany
Tissue culture plates: 48-well; Greiner Bio-One, Germany
Tissue culture plates: 96-well; Greiner Bio-One, Germany
Transfer membrane nitrocellulose; Bio-Rad, USA
Vasofix® Safety intravenous catheter; B. Braun, Germany
VersaMax micro-plate reader; Molecular Devices, USA
Vortex mixer; VWR, USA

3.1.2. Chemicals and reagents

2-Propanol; Merck, Germany
5-Aza-2′deoxycytidine; Sigma-Aldrich, Germany
Agarose; Promega, Germany
Agarose, low melting point; Sigma-Aldrich, Germany
Anti-CD16/32 antibody; BD Biosciences, USA
Anti-CD31 antibody; BD Biosciences, USA
Anti-CD45 antibody; BD Biosciences, USA
Anti-HDAC2 antibody (chromatin immunoprecipitation); Pierce Biotechnology, USA
Ammonium chloride; Sigma-Aldrich, Germany
Ammonium persulfate; Promega, Germany
Materials and methods

Ampicillin sodium salt; Sigma-Aldrich, Germany
Bovine serum albumin; Sigma-Aldrich, Germany
Bromophenol blue; Sigma-Aldrich, Germany
Calcium chloride; Sigma-Aldrich, Germany
Complete™ protease inhibitor; Roche, Germany
Deoxycholate; Sigma-Aldrich, Germany
Dispase; BD Biosciences, USA
3,3′-Dithiodipropionic acid di(N-hydroxysuccinimide ester); Sigma-Aldrich, Germany
DMSO; Sigma-Aldrich, Germany
DNase I; Serva, Germany
dNTP mix; Promega, USA
DTT; Promega, USA
Dual-Luciferase® reporter assay system; Promega, USA
Dulbecco’s modified Eagle's medium; Gibco BRL, Germany
Dulbecco’s modified Eagle's medium, high glucose; Gibco BRL, Germany
Dulbecco’s phosphate buffered saline, 10×; PAA Laboratories, Austria
Dulbecco’s phosphate buffered saline, 1×; PAA Laboratories, Austria
Dynabeads®, streptavidin-coupled; Invitrogen, UK
EDTA; Sigma-Aldrich, Germany
EGTA; Sigma-Aldrich, Germany
Ethanol 70%; SAV-LP, Germany
Ethanol 99%; J.T. Baker Mallinckrodt Baker B.V., Netherlands
Ethanol absolute; Riedel-de Haën, Germany
Ethidium bromide; Promega, USA
Evans blue; Sigma-Aldrich, Germany
Fetal calf serum; PAA Laboratories, Austria
Formaldehyde, 37%; Sigma-Aldrich, Germany
Formamide; Fluka, Germany
Giemsa’s azur eosin methylene blue solution; Merck, Germany
Glycerol; Carl Roth, Germany
Glycine; Carl Roth, Germany
Hank’s balanced salt solution; PAA Laboratories, Austria
HEPES; PAA Laboratories, Austria
HindIII restriction enzyme; Promega, USA
Hydrochloric acid; Sigma-Aldrich, Germany
Igepal® CA-630; Sigma-Aldrich, Germany
Isoflurane; CP-Pharma, Germany
Ketamine; Pharmacia & Upjohn, Sweden
Lipofectamine™ 2000; Invitrogen, UK
Lithium chloride; Sigma-Aldrich, Germany
Luria-Bertani medium; Invitrogen, UK
Magnesium chloride; Sigma-Aldrich, Germany
Magnesium chloride, 25 mM; Applied Biosystems, USA
May-Grünwald’s eosin-methylene blue solution; Merck, Germany
MC1568; Sigma-Aldrich, Germany
β-Mercaptoethanol; Sigma-Aldrich, Germany
Methanol; Fluka, Germany
MGCD0103; Selleck Chemicals, USA
MuLV reverse transcriptase; Applied Biosystems, USA
Non-fat dry milk; Carl Roth, Germany
Normal rabbit IgG; Santa Cruz Biotechnology, USA
NucleoBond® Xtra midi plasmid midiprep kit; Macherery-Nagel, Germany
NucleoSpin® RNA II kit; Macherery-Nagel, Germany
Nuclease-free water; Ambion, USA
Opti-MEM® medium; Gibco BRL, Germany
Passive lysis buffer; Promega, USA
PCR buffer II, 10×; Applied Biosystems, USA
Penicillin/streptomycin solution; PAA Laboratories, Austria
pGL3-Basic; Promega, USA
Platinum® SYBR® Green qPCR SuperMix UDG kit; Invitrogen, USA
Pierce® BCA protein assay kit; Thermo Scientific, USA
Potassium bicarbonate; Sigma-Aldrich, Germany
Precision Plus Protein™ standards; Bio-Rad, USA
pRL-SV40; Promega, USA
Protein A/G PLUS-agarose; Santa Cruz Biotechnology, USA
Proteinase K; Promega, USA
QIAquick gel extraction kit; Qiagen, Netherlands
QIAquick PCR purification kit; Qiagen, Netherlands
Materials and methods

Quick Start™ Bradford dye reagent; Bio-Rad, USA
Random hexamers; Applied Biosystems, USA
RIPA buffer; Thermo Scientific, USA
RNase inhibitor; Applied Biosystems, USA
Rompun®; Bayer, Germany
Rotiphorese Gel 30 acrylamide/bisacrylamide mixture; Carl Roth, Germany
SacI restriction enzyme; Promega, USA
SB431542; Calbiochem, USA
SDS, 10% solution; Promega, USA
SDS, powder; Carl Roth, Germany
Select agar; Sigma-Aldrich, Germany
Sonicated salmon sperm DNA; Agilent, USA
Sodium acetate; Sigma-Aldrich, Germany
Sodium bicarbonate; Sigma-Aldrich, Germany
Sodium chloride; Merck, Germany
Sodium orthovanadate; Sigma-Aldrich, Germany
Sodium phosphate; Sigma-Aldrich, Germany
Sodium sulfate; Merck, Germany
SuperSignal® West Femto chemiluminescent substrate; Thermo Scientific, USA
TEMED; Bio-Rad, USA
TGF-β1; R&D Systems, USA
Trichostatin A; Sigma-Aldrich, Germany
Tris; Carl Roth, Germany
Triton X-100; Promega, USA
TRIzol® reagent; Ambion, USA
Trypan blue; Fluka, Germany
Trypsin/EDTA; Gibco BRL, Germany
Tween® 20; Sigma-Aldrich, Germany

3.1.3. Cell lines

A549 epithelial cell line, human lung adenocarcinoma; ATCC-LGC, Germany
3.2. Methods

3.2.1. Human lung material

All investigations involving human material were approved by the University of Giessen Ethics Committee (approval number 29/01). Lung tissue was collected at autopsy from five ARDS patients, and from four patients who died of myocardial infarction, with no signs of pulmonary disease. Patients with ARDS met all American-European consensus conference on ARDS clinical criteria and required mechanical ventilation for a mean duration of 92 h. The clinical characteristics of these patients are presented in Table 1.

Table 1. The clinical characteristics of acute respiratory distress syndrome patients.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Sex</th>
<th>Background</th>
<th>Modified APACHE II</th>
<th>PaO$_2$/FiO$_2$ (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>40</td>
<td>female</td>
<td>Pneumonia</td>
<td>11</td>
<td>83.0</td>
</tr>
<tr>
<td>2</td>
<td>51</td>
<td>female</td>
<td>Trauma</td>
<td>6</td>
<td>181.5</td>
</tr>
<tr>
<td>3</td>
<td>48</td>
<td>female</td>
<td>Pancreatitis</td>
<td>20</td>
<td>127.2</td>
</tr>
<tr>
<td>4</td>
<td>59</td>
<td>female</td>
<td>Trauma</td>
<td>16</td>
<td>137.1</td>
</tr>
<tr>
<td>5</td>
<td>67</td>
<td>male</td>
<td>Sepsis</td>
<td>20</td>
<td>109.0</td>
</tr>
</tbody>
</table>

Abbreviations: APACHE, acute physiology and chronic health evaluation; FiO$_2$, fraction of inspired oxygen; PaO$_2$, partial pressure of oxygen in arterial blood.

3.2.2. ATP1B1 promoter cloning

3.2.2.1. Sub-cloning of the ATP1B1 promoter from the pGEM-T Easy vector into the pGL3-Basic vector

The pGEM-T Easy-ATP1B1-promoter plasmid containing a 1837-base-pair (bp) fragment of the ATP1B1 gene promoter (-3075 to -1238 bp upstream from transcription start site) was created by Verena Arnoldt. In order to clone the ATP1B1 promoter into the firefly luciferase reporter vector pGL3-Basic, 0.2 μg of the pGEM-T Easy-ATP1B1-promoter plasmid was digested with HindIII and SacI restriction enzymes (6 units of each enzyme was used per reaction) for 1 h at 37 °C.
Materials and methods

Products of restriction were then analyzed on a 1.5% agarose gel containing 0.5 μg ethidium bromide. A single band migrating at approximately 1800 bp corresponding to the ATP1B1 promoter was then excised with a clean scalpel and purified using a QIAquick gel extraction kit according to the manufacturer instructions. Next, 100 ng of the ATP1B1 promoter DNA was mixed with 50 ng pGL3-Basic vector (previously digested with HindIII and SacI restriction enzymes) and ligated using T4 DNA Ligase at 4 °C overnight, thereby creating the pGL3-Basic-ATP1B1-promoter construct.

3.2.2.2. Plasmid transformation of competent cells

The XL1-Blue competent bacteria cells were transformed using a heat shock transformation protocol. Bacterial suspension (50 μl) was transferred into a 1.5 ml tube containing 2 μl of the ligation mixture (30 ng of DNA) and incubated for 20 min on ice. Next, bacteria were subjected to heat shock at 42 °C for 45 s and the tube was immediately transferred back to ice for 2 min. Then, 950 μl of Luria-Bertani medium (LB-medium) was added, and the tube was incubated at 37 °C for 1.5 h with shaking at 150 revolutions per minute (rpm). Thereafter, tubes were centrifuged at 3000 rpm for 5 min at room temperature (RT), after which, the supernatant was discarded and the bacterial pellet was resuspended in 100 μl of LB-medium. The bacterial suspension was then plated on LB-agar supplemented with 50 μg/ml ampicillin and incubated at 37 °C overnight.

3.2.2.3. Plasmid midi-preparation

A single bacteria colony was inoculated into 5 ml of LB-medium supplemented with 50 μg/ml ampicillin, and incubated for 8 h at 37 °C with shaking at 180 rpm. Thereafter, 2 ml of the bacterial pre-culture was transferred into an Erlenmeyer flask containing 200 ml of LB-medium supplemented with 50 μg/ml ampicillin and incubated overnight at 37 °C with shaking at 180 rpm. The pGL3-Basic-ATP1B1-promoter plasmid was then extracted from the bacteria culture using a NucleoBond® Xtra Midi kit according to the manufacturer’s instructions.
3.2.3. **A549 cell culture**

The human lung adenocarcinoma epithelial cell line A549 was cultured in tissue culture flasks in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS) at 37 °C, 5% CO₂ and 95-100% humidity. After 80-90% confluence was reached, cells were subcultured using a single wash with phosphate buffered saline (PBS) followed by incubation with 3 ml Trypsin-EDTA solution for 3 min at 37 °C. The trypsin activity was inhibited with 7 ml of DMEM containing 10% FCS. Next, the cell suspension was diluted 1:5 with DMEM medium supplemented with 10% FCS and transferred into the fresh tissue culture flask.

3.2.3.1. **Treatment of A549 cells**

The A549 cells were treated with 0, 2, 6 or 10 ng/ml TGF-β1 for 1, 2, 3, 24 or 48 h. Inhibition of TGF-β signaling pathway was achieved by use of SB431542 (20 μM) added to the media 1 h before TGF-β1 treatment. Inhibition of DNA methylation was achieved by use of 0.1 μM or 10 μM 5-Aza-2′deoxycytidine (5-Aza-2′-dC) added to the media 24 h before beginning of TGF-β1 stimulation, and replenished every 24 h over the duration of the experiment. Trichostatin A (TSA, 64 nM), MGCD0103 (10 μM) and MC1568 (10 or 20 μM) histone deacetylase inhibitors were added 24 h after TGF-β1 was introduced and were left for another 24 h.

3.2.3.2. **Transient transfection of short interfering RNA**

The Lipofectamine™ 2000 transfection reagent was used to transiently transfect A549 cells with siRNA. Cells were seeded one day prior transfection into a 12-well plate, and were 40-50% confluent at the time of transfection. In order to transfect the cells with 100 nM siRNA, 2 μl of Lipofectamine™ 2000 regent was added to 50 μl of Opti-MEM® serum-free medium and left for 5 h at RT. Next, siRNA oligonucleotides (listed in Table 2) dissolved in Opti-MEM® medium were added, and incubated for 20 min at RT. For transfection of cells with 200 nM siRNA, 4 μl of Lipofectamine™ 2000 regent was used. The transfection mixture was then added to the cells cultured in the DMEM medium supplemented with 10% FCS. Cells were cultured for 24, 48, 72 or 96 h under normal cell culture conditions or exposed to 10 ng/ml TGF-β1 after 24 or 48 h for additional 48 h.
### Table 2. List of siRNA oligonucleotides used in knock-down experiments.

<table>
<thead>
<tr>
<th>Target gene</th>
<th>Company</th>
<th>Catalog number</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E2F4</em></td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-29300</td>
</tr>
<tr>
<td><em>E2F5</em></td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-35250</td>
</tr>
<tr>
<td><em>HDAC1</em></td>
<td>Invitrogen, USA</td>
<td>1299001/HSS104725</td>
</tr>
<tr>
<td><em>HDAC2</em></td>
<td>Invitrogen, USA</td>
<td>1299001/HSS104728</td>
</tr>
<tr>
<td><em>HDAC3</em></td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-35538</td>
</tr>
<tr>
<td><em>RUNX2</em></td>
<td>Qiagen, Netherlands</td>
<td>SI00063000</td>
</tr>
<tr>
<td>scrambled siRNA</td>
<td>Ambion, USA</td>
<td>AM4611</td>
</tr>
<tr>
<td><em>SMAD2</em></td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-44338</td>
</tr>
<tr>
<td><em>SMAD3</em></td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-38376</td>
</tr>
<tr>
<td><em>SMAD4</em></td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-29484</td>
</tr>
<tr>
<td><em>SNAI1</em></td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-38398</td>
</tr>
<tr>
<td><em>SNON</em></td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-36518</td>
</tr>
<tr>
<td><em>YY1</em></td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-36863</td>
</tr>
</tbody>
</table>

#### 3.2.3.3. Transient transfection of DNA

The A549 cells were transiently transfected with DNA using Lipofectamine™ 2000 transfection reagent. Cells were seeded into a 48-well plate and incubated until a confluence of 50% was achieved. To transfect the cells, 0.75 μl of Lipofectamine™ 2000 regent was mixed with 49.25 μl of Opti-MEM® serum-free medium and left for 5 min at RT. This mixture was then combined with solution containing 300 ng of pGL3-Basic-ATP1B1-promoter firefly luciferase reporter combined with 7 ng of pRL-SV40 Renilla luciferase co-reporter plasmid in 48.2 μl of Opti-MEM® medium and incubated for 20 min. Thereafter, culture medium was exchanged with transfection mixture and cells were left for 5 h. Next, transfection medium was aspirated, fresh DMEM medium supplemented with 10% FCS was added, and cells were left for 48 h under normal cell culture conditions, or treated with 0, 2, 6 or 10 ng/ml TGF-β1. When histone deacetylation was studied, 64 nM TSA, 10 μM MGCD0103 or 10 μM MC1568 inhibitors were added 24 h after TGF-β1 was introduced. In the case of DNA methylation inhibition, 0.1 or 10 μM 5-Aza-2′-dC was added 24 h before transfection, and was reintroduced every 24 h.
3.2.4. Culture of primary mouse alveolar epithelial type II cells

3.2.4.1. Isolation of primary mouse alveolar epithelial type II cells

Primary AETII cells were isolated using the modified protocol published by Corti and collaborators (Corti et al., 1996). Adult male C57BL/6J mice were anesthetized with isoflurane. The abdomen was opened by midline incision and mice were exsanguinated by transection of the Arteria renalis. The diaphragm was then punctured, and after the lung was retracted, the chest was opened and the ribs were fixed laterally. The left atrium was then punctured and the lungs were perfused with Hank’s balanced salt solution via the right ventricle. The trachea was cannulated with a Vasofix® Safety intravenous catheter and 2 ml of dispase followed by 0.5 ml of 1% low-melting point agarose was injected to the lungs. After 5 min, the lungs were removed, transferred into 2 ml of dispase and incubated for 45 min at RT. The lungs were dissected in 7 ml of DMEM medium without FCS (supplemented with 0.01% DNase I) and incubated for 10 min at RT. The resulting crude cell suspension was sequentially filtered through 100-μm and 40-μm cell strainers followed by final filtration through 20-μm nylon mesh. The filtrate was then centrifuged at 130 g for 8 min at 4 °C and resuspended in 7 ml of erythrocyte lysis buffer and incubated for 5 min at RT. Erythrocyte lysis was stopped with 7 ml of PBS, cells were centrifuged at 130 g for 8 min at 4 °C and resuspended in 5 ml DMEM medium containing 10% FCS. The cells were then stained with trypan blue, counted using a Countess® Cell Counter and incubated with 0.75 μl biotinylated anti-CD16/32, 0.9 μl biotinylated anti-CD45 and 0.4 μl biotinylated anti-CD31 antibodies per 1 million cells, for 30 min at 37 °C. The cells were then washed with 5 ml of DMEM medium without FCS, and AETII cells were negatively selected using streptavidin-coupled Dynabeads® for 30 min at RT with gentle mixing followed by final centrifugation at 130 g for 8 min at 4 °C and resuspension in DMEM medium with 10% FCS.

<table>
<thead>
<tr>
<th>DMEM medium without FCS</th>
<th>Erythrocyte lysis buffer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMEM high glucose medium</td>
<td>0.1 mM Na₂EDTA, pH 7.4</td>
</tr>
<tr>
<td>10 mM HEPES, pH 7.2</td>
<td>0.154 M NH₄Cl</td>
</tr>
<tr>
<td>1% penicillin/streptomycin solution</td>
<td>10 mM KHCO₃</td>
</tr>
</tbody>
</table>
3.2.4.2. Treatment of primary mouse alveolar epithelial type II cells

The AETII cells were seeded on 12 mm diameter Snapwell™ inserts at a density of $5 \times 10^5$ cells/well. After 24 h, the culture medium was removed from the apical compartment and the cells were grown under the air-liquid conditions. The cells were then treated with 10 ng/ml TGF-β1 for 48 h. For HDAC inhibition, 64 nM TSA, 10 μM MGCD0103 or 10 μM MC1568 was added 24 h after TGF-β1 was introduced and incubated for another 24 h.

3.2.5. Dual-luciferase reporter assay

Firefly and Renilla luciferase activity in A549 cells transiently co-transfected with pGL3-Basic-ATP1B1-promoter firefly reporter and pRL-SV40 Renilla firefly co-reporter vectors was measured using the Dual-Luciferase® reporter assay system. The co-transfected cells were lysed in 100 μl passive lysis buffer for 10 min in RT, with shaking at 100 rpm. Next, 5 μl of the cell lysate was transferred into 96-well plate, loaded into a Centro LB 960 microplate luminometer, and the activities of firefly and Renilla luciferases were measured sequentially in each well. The luminescence measurement protocol was as follows: dispersion of 50 μl of LAR II reagent (firefly luciferase substrate), quantification of luminescence for 7 s, dispersion of 50 μl Stop & Glo® regent (containing inhibitor of firefly luciferase and substrate for Renilla luciferase) and quantification of luminescence for 7 s. The ATP1B1 promoter activity was expressed as ratio of firefly-to-Renilla luciferase luminescence signals.

3.2.6. Gene expression analysis

3.2.6.1. RNA isolation from lung tissue and from cell culture

Total lung RNA was isolated from 70-90 mg of tissue using 1 ml of TRIZol® reagent per 100 mg tissue. Lung tissue was homogenized in a Precellys®
24 homogenizer. Subsequently, 0.2 ml chloroform per 1 ml TRIzol® reagent used for homogenization was added and samples were centrifuged at 12000 g for 15 min at 4 °C. After phase separation, the aqueous phase was transferred into a fresh 1.5 ml tube, and samples were combined with 0.5 ml 2-Propanol per 1 ml TRIzol® reagent used for homogenization, and left for 10 min at RT. Next, samples were centrifuged at 12000 g for 10 min at 4 °C, the supernatant was removed and the RNA pellet was washed once with 1 ml of 75% ethanol. Quantification and purity of the isolated RNA was determined with a NanoDrop® ND 1000. The cDNA was synthesized from RNA preparations with A$_{260/280}$ absorbance ratio above 1.90.

The total RNA from cells in culture was isolated using a NucleoSpin® RNA II kit according to the manufacturer’s instructions. The quantification and purity of isolated RNA was determined with a NanoDrop® ND 1000. The cDNA was synthesized from RNA preparations with A$_{260/280}$ absorbance ratio above 1.90.

3.2.6.2. cDNA synthesis

Reverse transcription was performed on 500 ng of total RNA using MuLV reverse transcriptase and random hexamer oligodeoxynucleotides. To perform cDNA synthesis, 20 μl of RNA was denatured at 70 °C for 10 min, transferred onto ice, and supplemented with 20 μl of reverse transcription mixture. Afterwards, the mixture was incubated at 21 °C for 10 min, followed by an RNA synthesis step at 43 °C for 1 h 15 min. The final incubation at 99 °C for 5 min was performed to inactivate MuLV reverse transcriptase.

<table>
<thead>
<tr>
<th>Reverse transcription mixture</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>10× PCR buffer II</td>
<td>4 μl</td>
</tr>
<tr>
<td>25 mM MgCl$_2$</td>
<td>8 μl</td>
</tr>
<tr>
<td>H$_2$O</td>
<td>1 μl</td>
</tr>
<tr>
<td>Random hexamers</td>
<td>2 μl</td>
</tr>
<tr>
<td>RNase inhibitor</td>
<td>1 μl</td>
</tr>
<tr>
<td>10 nM dNTP mix</td>
<td>2 μl</td>
</tr>
<tr>
<td>MuLV reverse transcriptase</td>
<td>2 μl</td>
</tr>
<tr>
<td>Total volume</td>
<td>20 μl</td>
</tr>
</tbody>
</table>
3.2.6.3. Real-time quantitative PCR

Analysis of the gene expression at the mRNA level was performed by real-time quantitative polymerase chain reaction (qPCR) using a Platinum® SYBR® Green qPCR SuperMix UDG kit and a StepOnePlus™ Real-Time PCR System. Intron-spanning primer pairs specific to the target mRNA were designed using Primer-BLAST software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primers used in the gene expression analyses are listed in Table 3.

Table 3. Primers used for gene expression analysis.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Species</th>
<th>Forward and reverse primers sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATP1A1</td>
<td>human</td>
<td>5'-AGCTACCTGGCTTGCTCTGTCC-3' 5'-GCTGACTCAGAGGGCATCTCCTGC-3'</td>
</tr>
<tr>
<td>ATP1B1</td>
<td>human</td>
<td>5'-AAAAATACAAAGATTCAGCCCCAGAGG-3' 5'-AGCTTGGAATCTGCAGACCTTTTGC-3'</td>
</tr>
<tr>
<td>Atp1b1</td>
<td>mouse</td>
<td>5'-CCCCAAGACGTACAGGCTAGCCG-3' 5'-CTCGGCCCCCTTCTGCTTGTC-3'</td>
</tr>
<tr>
<td>FXYD1</td>
<td>human</td>
<td>5'-TCGCCGGGATCTTTACATCC-3' 5'-CCTCTCTCTCTCATGCTTCCC-3'</td>
</tr>
<tr>
<td>FXYD2</td>
<td>human</td>
<td>5'-AGCCGCTCTGACATGCCAGAAGGT-3' 5'-CTTCTATAGTCCATGGCCAG-3'</td>
</tr>
<tr>
<td>FXYD3</td>
<td>human</td>
<td>5'-GGCCACTGATCTGCGGAGGG-3' 5'-GCTGCTTCTGGCTGTCTG-3'</td>
</tr>
<tr>
<td>FXYD4</td>
<td>human</td>
<td>5'-AGCCTGGGAGGAAGG-3' 5'-GGGCTCTGCTGCTGCTG-3'</td>
</tr>
<tr>
<td>FXYD5</td>
<td>human</td>
<td>5'-GACCTGGGAGGAAGG-3' 5'-GGGCTCTGCTGCTGCTG-3'</td>
</tr>
<tr>
<td>FXYD6</td>
<td>human</td>
<td>5'-CTCTCTCACTGCGTACATCC-3' 5'-GCTCTGTGCTGCTGCTG-3'</td>
</tr>
<tr>
<td>FXYD7</td>
<td>human</td>
<td>5'-GGGCTCTGCTGCTGCTG-3' 5'-GCTCTGTGCTGCTGCTG-3'</td>
</tr>
<tr>
<td>HPRT1</td>
<td>human</td>
<td>5'-AGGACCCACGAGTGGTTG-3' 5'-GGCCTTGATTTCCTTCCA-3'</td>
</tr>
<tr>
<td>Hprt1</td>
<td>mouse</td>
<td>5'-GCTGACCTGCGATTAC-3' 5'-TTGGGCTGTACTGCTTA-3'</td>
</tr>
</tbody>
</table>

The thermal cycling conditions were as follows: 50 °C for 2 min, 95 °C for 5 min, 40 cycles of 95 °C for 5 s, 59 °C for 5 s, 72 °C for 30 s. The samples were then subjected to melting curve analysis to ensure amplification of a single, specific product and to exclude the possibility of primer-dimer formation. A constitutively expressed human HPRT1 or mouse Hprt1 reference gene was used as a reference gene for qPCR reactions. Target gene expression was assessed with the comparative Ct method (ΔCt method) and calculated with the equation: ΔCt = Ct_HPRT1 – Ct_target.
3.2.7. Protein expression analysis

3.2.7.1. Protein isolation

The entire protein isolation procedure was carried out on ice to prevent protein degradation. Protein lysis buffer was supplemented with 1 mM sodium orthovanadate and Complete™ protease inhibitor cocktail (1 tablet per 25 ml of protein lysis buffer) immediately before use. Next, 100 μl or 200 μl of protein lysis buffer was added to the A549 cells seeded on 6-well or 12-well plates, respectively, and cells were collected with a cell scraper into a 1.5 ml tube and incubated for 30 min with occasional vortexing. Tubes were then centrifuged at 13000 rpm for 15 min at 4 °C and the supernatant was then transferred into fresh 0.5 ml tubes. To measure protein concentration, samples as well as protein lysis buffer were diluted 1:10 with water and 10 μl was transferred into a 96-well plate. In parallel, a series of 10 μl of bovine serum albumin protein standards were included on the same plate. Subsequently, 100 μl of Quick Start™ Bradford dye regent was added to each well, plate was left for 5 min and the absorbance was measured at a 570 nm wavelength using a VersaMax micro-plate reader. Protein concentrations were calculated for each sample using a standard curve.

**Protein lysis buffer**
- 150 mM NaCl
- 1 mM EDTA
- 1 mM EGTA
- 0.5% Igepal® CA-630
- 20 mM Tris-Cl, pH 7.5

3.2.7.2. Protein electrophoresis and western blot

Protein samples were mixed with 10× sample buffer and resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis at 110 mV in running buffer. After the bromophenol blue tracking dye had left the resolving gel, proteins were blotted onto a nitrocellulose membrane at 110 mV for 1 h in blotting buffer. Next, the membrane was washed once with washing buffer and incubated for 1 h in blocking buffer at RT. Membranes were then incubated with primary antibody diluted in blocking buffer at 4 °C overnight. Primary antibodies used in the western blot analysis are listed in Table 4. After the membrane was rinsed in washing buffer four times for 3 min each, the
horseradish peroxidase-conjugated secondary antibody diluted in blocking buffer was then added, and the membrane was incubated for 1 h at RT. Thereafter, the membrane was rinsed four times for 3 min each in washing buffer, and was incubated in SuperSignal® West Femto chemiluminescent substrate for 3 min at RT. The protein bands were visualized and archived with a LAS-4000 luminescent image analyzer.

**Table 4. Primary antibodies used in western blot analysis.**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Dilution</th>
<th>Company</th>
<th>Catalog number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-β-ACTIN</td>
<td>1:1000</td>
<td>Cell Signaling Technology, USA</td>
<td>4967L</td>
</tr>
<tr>
<td>Anti-E2F4</td>
<td>1:100</td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-1082</td>
</tr>
<tr>
<td>Anti-E2F5</td>
<td>1:100</td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-999</td>
</tr>
<tr>
<td>Anti-HDAC1</td>
<td>1:500</td>
<td>Cell Signaling Technology, USA</td>
<td>2062</td>
</tr>
<tr>
<td>Anti-HDAC2</td>
<td>1:500</td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-6296</td>
</tr>
<tr>
<td>Anti-HDAC2</td>
<td>1:500</td>
<td>Abcam, UK</td>
<td>ab75602</td>
</tr>
<tr>
<td>(phospho S394)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-HDAC3</td>
<td>1:500</td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-8138</td>
</tr>
<tr>
<td>Anti-LAMIN A/C</td>
<td>1:5000</td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-20681</td>
</tr>
<tr>
<td>Anti-RUNX2</td>
<td>1:500</td>
<td>Invitrogen, USA</td>
<td>41-1400</td>
</tr>
<tr>
<td>Anti-SMAD2</td>
<td>1:1000</td>
<td>Cell Signaling Technology, USA</td>
<td>3103</td>
</tr>
<tr>
<td>(phospho S465/467)</td>
<td>1:1000</td>
<td>Cell Signaling Technology, USA</td>
<td>3101S</td>
</tr>
<tr>
<td>Anti-SMAD3</td>
<td>1:1000</td>
<td>Cell Signaling Technology, USA</td>
<td>3102</td>
</tr>
<tr>
<td>(phospho S423/425)</td>
<td>1:1000</td>
<td>Cell Signaling Technology, USA</td>
<td>9520S</td>
</tr>
<tr>
<td>Anti-SMAD4</td>
<td>1:500</td>
<td>Cell Signaling Technology, USA</td>
<td>9515</td>
</tr>
<tr>
<td>Anti-SNA1</td>
<td>1:500</td>
<td>R&amp;D Systems, USA</td>
<td>AF3639</td>
</tr>
<tr>
<td>Anti-SNON</td>
<td>1:500</td>
<td>Cell Signaling Technology, USA</td>
<td>4973</td>
</tr>
<tr>
<td>Anti-YY1</td>
<td>1:500</td>
<td>Santa Cruz Biotechnology, USA</td>
<td>sc-7341</td>
</tr>
</tbody>
</table>

**10× Sample buffer**
- 650 mM Tris-Cl, pH 6.8
- 1 mM EDTA
- 50% glycerol
- 0.3% bromophenol blue
- 9% β-mercaptoethanol

**10% Resolving gel**
- 10% acrylamide/bisacrylamide mixture
- 375 mM Tris-Cl, pH 8.8
- 0.05% SDS
- 0.05% APS
- 0.065% TEMED
3.2.8. Chromatin immunoprecipitation

Chromatin immunoprecipitation (ChIP) assay was performed on A549 cells plated on 60 mm dishes. Cells were cultured until 90% confluence was reached and stimulated with 10 ng/ml TGF-β1 for 3 h. Cells were then washed with PBS twice, and subjected to dual cross-linking with 1 mM 3,3′-Dithiodipropionic acid di(N-hydroxysuccinimide ester) (DSP) in PBS for 30 min followed by incubation with 1% formaldehyde for 10 min at RT, with shaking at 100 rpm. Cross-linking was quenched with 125 mM glycine for 5 min at RT. After a single washing step with PBS, the procedure was carried out on ice to prevent the degradation of protein and DNA. Cells were lysed for 10 min in 1 ml of RIPA buffer supplemented with 1 mM sodium orthovanadate and Complete™ protease inhibitor cocktail (1 tablet per 25 ml of RIPA buffer). The lysate was collected with a cell scraper into a 1.5 ml tube and chromatin was sheared into 200-300 bp-long fragments using a Sonopuls HD 2070 ultrasonic homogenizer using the following settings: 7 rounds of 10 pulses with 40% duty cycle and 40% power output settings. The lysate was then centrifuged at 14000 rpm for 15 min, and the supernatant was collected. The 163 μl of supernatant was diluted 1:6 in RIPA buffer and pre-cleared with 50 μl protein A/G agarose beads saturated with 10 μg of sonicated salmon sperm DNA for 1 h with gentle orbital rotation. After the centrifugation at 3000 rpm for 4 min, protein A/G agarose beads were discarded, and the immunoprecipitation was carried out with 20 μg of anti-HDAC2 or normal rabbit IgG.
antibodies added to the pre-cleared chromatin lysate. Two hours later, 50 μl protein A/G agarose beads saturated with 10 μg of sonicated salmon sperm DNA was added and left overnight with gentle orbital rotation. Antibody-chromatin complexes conjugated to protein A/G agarose beads were then sequentially washed with 1 ml of low salt buffer, 1 ml high salt buffer, 1 ml LiCl buffer and twice with 1 ml TE buffer. Each washing step was conducted for 5 min followed by centrifugation at 3000 rpm for 3 min at RT and removal of the supernatant. To elute antibody-chromatin complexes, 150 μl elution buffer was added and samples were incubated for 30 min at 65 °C with shaking at 500 rpm. Samples were centrifuged at 3000 rpm for 3 min at RT and the supernatant was saved in a fresh 1.5 ml tube. To test the efficiency of the antibody to immunoprecipitate HDAC2, 36 μl of eluate or input samples was subjected to protein electrophoresis and western blot as described above. To purify DNA from protein, immunoprecipitated chromatin was reverse cross-linked at 65 °C followed by addition of 50 mM DTT and incubation for 30 min at 37 °C and 0.5 μg/ml proteinase K treatment for 30 min at 55 °C. The DNA was further purified using QIAquick PCR purification kit according to the manufacturer instructions. Semi-quantitative PCR and qPCR were then performed using Platinum® SYBR® Green qPCR SuperMix UDG kit on 4 ng of DNA. Primers used in the ChIP experiments are listed in Table 5. The product of the semi-quantitative PCR were resolved on 3% agarose gel containing 0.5 μg ethidium bromide and archived using X Omat 2000 developer.

<table>
<thead>
<tr>
<th>Low salt buffer</th>
<th>LiCl buffer</th>
<th>TE buffer</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1% SDS</td>
<td>0.25 M LiCl</td>
<td>1 mM EDTA</td>
</tr>
<tr>
<td>1% Triton X-100</td>
<td>1% Igepal® CA-630</td>
<td>10 mM Tris-Cl, pH 8.0</td>
</tr>
<tr>
<td>2 mM EDTA</td>
<td>1% deoxycholate</td>
<td></td>
</tr>
<tr>
<td>20 mM Tris-Cl, pH 8.0</td>
<td>1 mM EDTA</td>
<td></td>
</tr>
<tr>
<td>150 mM NaCl</td>
<td>10 mM Tris-Cl, pH 8.0</td>
<td></td>
</tr>
<tr>
<td>High salt buffer</td>
<td>TE buffer</td>
<td>Elution buffer</td>
</tr>
<tr>
<td>0.1% SDS</td>
<td>1 mM EDTA</td>
<td>1% SDS, pH 8.0</td>
</tr>
<tr>
<td>1% Triton X-100</td>
<td>10 mM Tris-Cl, pH 8.0</td>
<td>0.1 M NaHCO₃, pH 8.0</td>
</tr>
<tr>
<td>2 mM EDTA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 mM Tris-Cl, pH 8.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>500 mM NaCl</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 5. Primers used in chromatin immunoprecipitation experiments.

<table>
<thead>
<tr>
<th>Locus</th>
<th>Forward and reverse primers sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATP1B1 promoter</td>
<td>5’-CCCCCAAGGGGACATAAAAGCA-3’</td>
</tr>
<tr>
<td></td>
<td>5’-AGGCACAATATCTGCACGTGACC-3’</td>
</tr>
<tr>
<td>HPRT1 exon three</td>
<td>5’-ACGTCTTGTGAGATGATGAT-3’</td>
</tr>
<tr>
<td></td>
<td>5’-GATGTAATCCAGCAGTCAGC-3’</td>
</tr>
</tbody>
</table>

3.2.9. Animal experiments

3.2.9.1. The bleomycin model of acute respiratory distress syndrome and trichostatin A treatment

Animal experiments were approved by local authorities (Regierungspräsidium Darmstadt, approval number B 2/281). Male mice (C57BL/6J) were obtained from Charles River Laboratories, Sulzfeld, Germany. Only animals weighing 20-25 g were used in the study. Mice were anesthetized with mixture of 100 mg ketamine per kg body weight and 8 mg xylazine per kg body weight. Thereafter, mice were orotracheally intubated and mechanically ventilated. Bleomycin (5 U per kg body weight) or 0.9% saline was then intratracheally instilled using a microsprayer. After 24 h, mice received an intraperitoneal injection of 0.5 mg TSA per kg body weight or 0.9% saline which was repeated daily for 3 subsequent days. At the conclusion of the experiment, mice were sacrificed with 500 mg pentobarbital per kg body weight.

3.2.9.2. Lung tissue collection and weight measurements

After the thoracic cavity was exposed, lungs were perfused with 1× PBS injected via the right ventricle. The trachea was then dissected and lung was removed. The right lung was snap-frozen in liquid nitrogen and subjected to RNA isolation and gene expression analysis as described above. The left lobe was used to assess the lung wet-to-dry weight ratio by the gravimetric method. After the wet lung weight was measured, the lung was incubated at 60 °C for 72 h in an oven. Then, the dry lung weight was measured and ratio between wet and dry left lung weights was calculated.
3.2.9.3. Broncho-alveolar lavage

The lung and trachea were exposed as described above. After the lung was cannulated via the trachea, the left main bronchus was clamped and the right lung was lavaged three times with 300 μl 0.9% NaCl. The clamp was then removed, attached to the right main bronchus, and the lavage was collected from the left lung. The BAL fluid was collected after each wash and pooled. Subsequently, BAL fluid was centrifuged at 1780 rpm for 10 min at 4 °C. The supernatant and cell pellet were collected separately and used for protein concentration measurements and analyses of inflammatory cell populations, respectively.

3.2.9.4. Measurement of protein concentration in broncho-alveolar lavage fluid

To measure protein concentration, 10 μl BAL fluid supernatant, 0.9% NaCl and bovine serum albumin protein standard were transferred into a 96-well plate. Next, 200 μl of Pierce® BCA protein assay reagent was added to each well, plate was incubated at 37 °C for 30 min and absorbance was measured at 562 nm wavelength using a VersaMax micro-plate reader. Protein concentrations in BAL fluid were calculated for each sample using a standard curve.

3.2.9.5. Analysis of inflammatory cell populations

The cell pellet formed after BAL fluid centrifugation was resuspended in 1 ml of 0.9% NaCl. Subsequently, 100 μl of cell suspension was loaded onto assembled CellSpin preparation system and centrifuged at 500 rpm for 5 min. Slides were then dried and cells were stained with May-Grünwald solution for 5 min followed by incubation in Giemsa solution diluted 1:10 in water for 10 min. The differential cell count of alveolar macrophages, neutrophils and lymphocytes was then made under a light microscope and expressed as a percentage of the total cell population in the BAL fluid.
3.2.9.6. Evans blue extravasation assay

Evans blue dye (20 mg per kg body of weight) was injected into the tail vein 3 h before mice were sacrificed. At the time of killing, 1 ml of blood was collected by cardiac puncture, centrifuged at 1300 rpm for 10 min at RT and the blood plasma was diluted in formamide 1:100. The lung was perfused with PBS via the right ventricle, homogenized in a Precellys® 24 homogenizer and diluted in two volumes of formamide. Blood plasma and lung homogenate samples diluted in formamide were then incubated at 60 °C for 16 h to extract the Evans blue dye. Subsequently, the lung homogenate was centrifuged at 5000 g for 30 min at RT and the pellet was discarded. The absorbance of Evans blue in blood plasma and lung homogenate was then measured at 620 nm and corrected for the presence of heme by absorbance measurements at 740 nm. The corrected Evans blue absorption was then calculated as follows:

$$A_{620\ (corrected)} = A_{620} - (1.426 \times A_{740} + 0.03)$$

for lung homogenates and blood plasma. The Evans blue index reflecting the microvascular permeability of the dye was expressed as ratio of $A_{620\ (corrected)}$ in the lung homogenate to the $A_{620\ (corrected)}$ in the blood plasma.

3.3. Statistical analyses

Values are presented as mean ± SEM. Statistical comparisons between means of two groups were performed using unpaired Student’s t-tests. For multiple comparisons, statistical analysis was performed using one-way ANOVA followed by a Tukey’s post-hoc test. P-values less than 0.05 were considered significant.
4. Results

4.1. Pulmonary expression of genes encoding Na,K-ATPase subunits in lungs from acute respiratory distress syndrome patients and in healthy lung tissue

The expression of the ATP1A1, ATP1B1 and FXYD1-FXYD7 genes encoding Na,K-ATPase subunits in lung tissue from patients with ARDS was analyzed by qPCR. The expression of genes in lung homogenates was compared between four donors and five ARDS patients. The downregulation of ATP1B1 gene expression was noted in samples from ARDS patients when compared to apparently healthy lung donors as depicted in Figure 6. Moreover, the expression of the FXYD1 and FXYD3 genes was significantly upregulated in ARDS patients, while ATP1A1, FXYD2 and FXYD4-FXYD7 gene expression remained unchanged comparing the two sample groups.

---

**Figure 6.** Pulmonary expression of genes encoding Na,K-ATPase subunits in donor versus ARDS patients. The expression of the ATP1A1, ATP1B1 and FXYD1-FXYD7 genes was assessed in lung tissue from five patients with ARDS or four healthy lung donors by qPCR. Data are expressed as mean ± SEM.
4.2. TGF-β alters the expression of genes encoding Na,K-ATPase subunits in A549 cells

The A549 cell-line is frequently used as a model for the human alveolar epithelium. In order to verify whether TGF-β has a regulatory role governing the expression of genes encoding Na,K-ATPase subunits in an epithelial-like cell-line, qPCR analysis was performed. Figure 7 depicts the diverse effect of TGF-β on the expression of Na,K-ATPase subunits encoding genes.

![Graphs showing the expression of Na,K-ATPase subunits in TGF-β treated A549 cells.](image)

**Figure 7.** Expression of genes encoding Na,K-ATPase subunits in TGF-β-treated A549 cells. The expression of the ATP1A1, ATP1B1 and FXYD1-FXYD7 genes was assessed in the A549 cells stimulated with 0-10 ng/ml of TGF-β1 for 24 h or 48 h by qPCR (n=3, per group). Data are expressed as mean ± SEM.
The TGF-β treatment induced expression of *ATP1A1, FXYD1, FXYD5* and *FXYD6* genes and decreased the expression of *ATP1B1, FXYD2, FXYD3* and *FXYD4* genes. The expression of *FXYD7* remained unaffected. Furthermore, the effect of TGF-β on *FXYD3* mRNA abundance was time-dependent as only TGF-β treatment for 48 h but not 24 h caused repression of this gene. Additionally, genes *ATP1A1, FXYD1, FXYD2, FXYD5* and *FXYD6* were dose-dependently regulated by TGF-β.

**4.3. Inhibition of TGF-β signaling restores *ATP1B1* gene expression**

TGF-β utilizes SMAD2 and SMAD3 transcription factors as primary mediators of the TGF-β-regulated gene expression program. To test whether SMAD2 and SMAD3 were implicated in regulation of the *ATP1B1* gene, A549 cells were pre-treated with SB431542, a selective inhibitor of the TBRI receptors, ALK4, ALK5 and ALK7, and then stimulated with TGF-β. As demonstrated in Figure 8A and 8B, treatment with SB431542 drastically reduced phosphorylation of the SMAD2 and SMAD3 in the TGF-β-treated cells. Furthermore, SB431542 prevented repression of the *ATP1B1* gene indicating that TGF-β signaling employs R-SMADs to regulate expression of the *ATP1B1* gene (Figure 8C).

**Figure 8. Inhibition of the TGF-β type I receptor alleviates *ATP1B1* gene repression by TGF-β.** The impact of SB431542 on the phosphorylation of SMAD2 (A) and SMAD3 (B). The A549 cells were first treated with 20 μM SB431542 for 1 h followed by stimulation with 10 ng/ml TGF-β1 for 1 h. Total cellular proteins were isolated, subjected to western blot and immunohistochemically stained with antibodies against phosphorylated SMAD2, phosphorylated SMAD3, total SMAD2, total SMAD2/SMAD3 and β-ACTIN. (C) Expression analysis of the *ATP1B1* gene was assessed in A549 cells stimulated with 0 ng/ml or 10 ng/ml of TGF-β1 for 48 h, by qPCR. The 20 μM SB431542 was added 1 h before the TGF-β1 stimulation for 49 h (n=3, per group). Data are expressed as mean ± SEM.
4.4. TGF-β downregulates $ATP1B1$ gene expression via SMAD2, SMAD4, SNAI1 and E2F5 transcription factors

TGF-β signaling is a complex process involving the activity of many different transcription factors in order to achieve precise regulation of target gene expression. In order to characterize the transcription factors involved in the TGF-β-dependent down-regulation of the $ATP1B1$ gene, a series of knock-down experiments was performed. Lipofectamine™ 2000-mediated delivery of siRNA molecules designed against TGF-β signaling-associated transcription factors was selected to take advantage of the relatively efficient transfection rates of A549 cells using cationic lipid formulations. At the 24 h or 48 h time-point before TGF-β stimulation, A549 cells were transfected with 100 nM or 200 nM siRNA targeting the SMAD2, SMAD3, SMAD4, YY1, RUNX2, TGF, SNON, SNAI1, E2F4 and E2F5 transcription factors, which led to a marked decrease in protein abundance as demonstrated by western blot (Figure 9).

Figure 9. Optimization of siRNA knock-down of transcription factors involved in TGF-β signaling. The A549 cells were transfected with 100 nM or 200 nM of scrambled (scr) siRNA or siRNA designed against SMAD2 (A), SMAD3 (B), SMAD4 (C), YY1 (D), RUNX2 (E), SNON (F), SNAI1 (G), E2F4 (H) or E2F5 (I) for 24 h and 72 h or 48 h and 96 h. A western blot was used to confirm the knock-down of transcription factor proteins.
An analysis of *ATP1B1* gene expression by qPCR revealed that the depletion of SMAD3, YY1, RUNX2, TGIF, SNON and E2F4 transcription factors did not impact the ability of TGF-β to down-regulate the *ATP1B1* gene expression (Figure 10B, 10D-F and 10H). However, the *ATP1B1* gene was relieved from repression by TGF-β in cells where SMAD2, SMAD4, SNAI1 or E2F5 were depleted by knock-down (Figure 10A, 10C, 10G and 10I). These data indicate that SMAD2, SMAD4, SNAI1 and E2F4 mediate the downregulation of *ATP1B1* gene expression by TGF-β.

Figure 10. Regulation of the *ATP1B1* gene by TGF-β signaling-associated transcription factors. Expression of the *ATP1B1* gene in A549 cells with knock-down of SMAD2 (A), SMAD3 (B), SMAD4 (C), YY1 (D), RUNX2 (E), SNON (F), SNAI1 (G), E2F4 (H) or E2F5 (I) transcription factors. The A549 cells were transfected with 100 nM or 200 nM of siRNA. At 24 h or 48 h later, 10 ng/ml of TGF-β1 was added to transfection medium for additional 48 h. The expression of *ATP1B1* gene was then analyzed by qPCR (n=3, per group). Data are expressed as mean ± SEM.
4.5. TGF-β downregulates $ATP1B1$ promoter activity

To confirm that TGF-β signaling controls the expression of the $ATP1B1$ gene at the level of gene transcription, the 1837-bp DNA fragment spanning the upstream region of the $ATP1B1$ gene (-3075 to -1238 bp upstream from transcription start site) was cloned into pGL3-Basic vector. The activity of the $ATP1B1$ promoter was measured by a dual-luciferase reporter assay. TGF-β significantly decreased the activity of $ATP1B1$ promoter (Figure 11A) revealing that TGF-β inhibits the expression of the $ATP1B1$ gene on the transcription level.

Figure 11. The $ATP1B1$ promoter analysis in A549 cells treated with TGF-β. (A) A dual-luciferase reporter assay of $ATP1B1$ gene promoter activity. Cells were transiently co-transfected with a pGL3-Basic-$ATP1B1$-promoter firefly luciferase reporter plasmid and pRL-SV40 Renilla luciferase co-reporter vector and were then stimulated with 0-10 ng/ml TGF-β1 for 48 h ($n$=4, per group). Data are expressed as mean ± SEM. (B) Schematic representation of 3 kbp region of the $ATP1B1$ promoter. Novel putative bindings sites for E2F5 (-2118 bp) and SNAI1 (-1562 bp) along previously characterized SNAI1 binding site (-71 bp) are shown. (C) Sequence comparison of the E2F5 binding element from c-myc promoter to putative E2F5 binding site in the $ATP1B1$ promoter. Differing nucleotides are underlined.

Sequence analysis of the promoter region spanning 3000 bp upstream from the transcriptional start site revealed the presence of putative binding sites for SNAI1 and E2F5 transcription factors. The noncanonical E-box element, a SNAI1-binding sequence, located within -71 to -66 bp upstream from transcription start site was previously characterized (Espineda et al., 2004). Analysis of the further upstream regions of the promoter uncovered a site identical in sequence to the E-box element (5’-CCGGTG-3’) characterized by Espineda et al. albeit -1562 to -1557 bp upstream from the transcriptional start site (Figure 11B). Additionally, a site highly similar
to the E2F5-binding element reported by Chen and coworkers was located at -2118 to -2110 bp (Figure 11C). The putative E2F5 binding site localized in the ATP1B1 gene promoter varied from the TGF-β responsive element described in the c-myc promoter by the presence of the single thymine base instead of the guanine at position seven of the sequence (Chen et al., 2002).

4.6. The TGF-β-dependent down-regulation of ATP1B1 gene expression is mediated by DNA methylation and class I histone deacetylases

To test whether inhibition of ATP1B1 expression by TGF-β involves the action of the epigenetic machinery, 5-Aza-2’-dC and TSA were employed to inhibit DNA methylation and histone deacetylation, respectively. Prevention of DNA methylation by 5-Aza-2’-dC abolished TGF-β-triggered downregulation of the ATP1B1 gene expression as assessed by qPCR (Figure 12A). Additionally, the influence of DNA methylation on the ATP1B1 promoter was tested. The treatment with 5-Aza-2’-dC alone reduced the activity of the ATP1B1 promoter to the level observed under the TGF-β conditions. Moreover, TGF-β did not further reduce the activity of the ATP1B1 promoter in A549 cells co-treated with 5-Aza-2’-dC (Figure 12B).

Figure 12. Activity of the ATP1B1 gene and promoter is regulated by DNA methylation. (A) Analysis of ATP1B1 gene expression in A549 cells stimulated with 0 ng/ml or 10 ng/ml of TGF-β1 for 48 h by qPCR (n=3, per group). 24 h before TGF-β1 treatment and at the 0 h and 24 h time-points after TGF-β1 stimulation, 0, 0.1 or 10 μM 5-Aza-2’-deoxycytidine (5-Aza-2’-dC) was added. (B) A dual-luciferase reporter assay of the ATP1B1 promoter activity (n=9, per group). Cells were stimulated with TGF-β1 or 5-Aza-2’-dC as in (A). Data are expressed as mean ± SEM.
To test whether TGF-β signaling recruits HDACs to repress the \textit{ATP1B1} gene, the pan-HDAC inhibitor, TSA, was used. Histone deacetylase inhibition abrogated the repression of the \textit{ATP1B1} gene by TGF-β (Figure 13A). Moreover, the involvement of HDACs in the repression was further confirmed by evidence of decreased \textit{ATP1B1} promoter activity in the TGF-β stimulated cells co-treated with TSA (Figure 13C). To characterize the nature of the complexes repressing the \textit{ATP1B1} gene, class-specific inhibitors of HDAC enzymes were employed. The TGF-β-induced repression of the \textit{ATP1B1} gene was specifically facilitated by class I HDAC enzymes, since use of the class I HDAC inhibitor MGCD0103 but not MC1568 (a class II HDAC inhibitor) removed the TGF-β effect (Figure 13B). Moreover, the involvement of class I HDAC has been verified by promoter activity assay, where MGCD0103 alleviated the response to TGF-β, while use of the class II HDAC inhibitor did not repeat this result (Figure 13C).

**Figure 13.** Class I histone deacetylases regulate \textit{ATP1B1} gene expression and promoter activity. (A), (B) and (C) The A549 cells were stimulated with 0 ng/ml or 10 ng/ml of TGF-β1 for 48 h. At 24 h after TGF-β1 was added, 64 nM pan-HDAC inhibitor trichostatin A (TSA), 10 μM (C) class I or class II HDAC inhibitors (MGCD0103 or MC1568, respectively) were added for 24 h (n=3-4, per group). (A) and (B) Expression of the \textit{ATP1B1} was assessed by qPCR. (C) A dual-luciferase reporter assay of the \textit{ATP1B1} promoter activity (n=3, per group). Data are expressed as mean ± SEM.
4.7. Histone deacetylase 2 mediates repression of the \textit{ATP1B1} gene by TGF-\(\beta\)

To characterize which member of the class I HDACs repress \textit{ATP1B1} gene expression after TGF-\(\beta\) stimulation, the siRNA approach was employed to knock-down HDAC1, HDAC2 and HDAC3 proteins. As demonstrated in Figure 14A-C, the control western blot confirmed that siRNA transfections decreased the abundance of HDAC1, HDAC2 and HDAC3 proteins. The knock-down of the HDAC2 expression by siRNA resulted in a diminished effect of TGF-\(\beta\) on \textit{ATP1B1} gene expression (Figure 14E). This effect was specific only to cells displaying HDAC2 knock-down, since depletion of HDAC1 or HDAC3 did not impact \textit{ATP1B1} gene repression (Figure 14D and 14F).

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure14}
\caption{A particular role for histone deacetylase 2 in the regulation of \textit{ATP1B1} gene repression. Optimization of siRNA knock-down of HDAC1 (A), HDAC2 (B) or HDAC3 (C) transcription co-factors. The A549 cells were transfected with 200 nM of scrambled (scr) siRNA or siRNA designed against one of the HDAC-encoding mRNA for 24 and 72 or 48 and 96 h. A western blot was used to confirm knock-down of HDAC protein. Expression of the \textit{ATP1B1} gene in A549 cells with knock-down of HDAC1 (D), HDAC2 (E) or HDAC3 (F) proteins. The A549 cells were transfected with 200 nM of siRNA. At 24 or 48 h later, 10 ng/ml of TGF-\(\beta\)1 was added to transfection medium for additional 48 h. The expression of the \textit{ATP1B1} gene was then analyzed by qPCR (\(n=3\), per group). Data are xpressed as mean \pm SEM.}
\end{figure}
4.8. Histone deacetylase 2 occupies the $\textit{ATP1B1}$ promoter and is activated by TGF-β

To investigate whether HDAC2 can be located in the $\textit{ATP1B1}$ gene promoter a ChIP technique was employed. In principle, the ChIP assay allows for the detection of a specific DNA sequence which interacts with immunoprecipitated proteins of interest. As a transcriptional co-repressor, HDAC2 does not bind DNA directly, and is not located in close proximity to DNA, which limits the effectiveness of the short-arm cross-linker formaldehyde that is commonly used in the ChIP assay. In the present study, the DNA-protein cross-linking procedure was modified by the introduction of the long-arm cross-linker DSP to capture the weak association between HDAC2 and DNA. Immunoprecipitation of the HDAC2 was confirmed by western blot by identification of a band migrating with a molecular mass of 55 kDa (Figure 15A). As a 55 kDa band was not detected when an isotype control antibody was used instead of an anti-HDAC2 antibody, the specificity of the HDAC2 immunoprecipitation was confirmed. Analysis of DNA cross-linked to HDAC2 by PCR resulted in amplification of $\textit{ATP1B1}$ promoter region located -1339 to -1241 bp upstream from the transcriptional start site (Figure 15B). The TGF-β treatment for 3 h did not impact the intensity of the -1339 to -1241 bp amplicon, suggesting that TGF-β does not increase $\textit{ATP1B1}$ promoter occupancy by HDAC2. The absence of DNA amplification when an isotype control antibody was used confirmed the specificity of the ChIP. To further test the specificity of the ChIP assay, exon three of the reference gene $\textit{HPRT1}$ was chosen to represent a region potentially uninvolved in transcriptional regulation and HDAC2 binding. No DNA amplification was observed when semiquantitative PCR with primers recognizing exon three in $\textit{HPRT1}$ gene was performed on chromatin immunoprecipitated with an anti-HDAC2 or isotype control antibody (Figure 15C). These data suggest that immunoprecipitates were not contaminated with DNA fragments which were not bound to HDAC2. To obtain quantitative data for TGF-β impact on the sequestration of the HDAC2 to the $\textit{ATP1B1}$ promoter, a qPCR technique was employed. As illustrated in Figure 15D, TGF-β treatment did not significantly induce the accumulation of HDAC2 in region -1339 to -1241 bp of the $\textit{ATP1B1}$ promoter, thereby confirming that TGF-β does not increase the occupancy of HDAC2 on the $\textit{ATP1B1}$ promoter.
Since TGF-β treatment did not increase enrichment of HDAC2 at the ATP1BI promoter site, the possibility that TGF-β signaling can regulate HDAC2 activity was investigated. The phosphorylation of HDAC2 at serine 394 has been linked to increased enzymatic activity and speculated to be an important step allowing the formation of repressor complexes (Tsai and Seto, 2002). Therefore, the impact of TGF-β on the phosphorylation at serine 394 of HDAC2 was evaluated by western blot. As depicted in Figure 16, treatment with TGF-β increased phosphorylation of serine 394 which was observed over 3 h time course after stimulation indicating that TGF-β signaling can activate HDAC2.
Results

Figure 16. Impact of TGF-β on the phosphorylation status of HDAC2. The A549 cells were stimulated with 0 ng/ml or 10 ng/ml of TGF-β1 for 1, 2 or 3 h. Total cellular proteins were isolated, subjected to western blot and immunochemically stained with antibodies against HDAC2 phosphorylated at serine 394, total HDAC2 and LAMIN A/C (n=4, per group).

4.9. Downregulation of the Atp1b1 gene in TGF-β-stimulated alveolar epithelial type II cells can be reversed by inhibition of class I histone deacetylases

Isolated primary mouse AETII cells were used to verify whether TGF-β regulates Atp1b1 gene expression in epithelial cells in primary culture. As demonstrated in Figure 17, treatment with TGF-β for 48 h resulted in repression of the Atp1b1 gene in primary AETII cells cultured under air-liquid conditions.

To test whether HDAC proteins mediate regulation of the Atp1b1 gene by TGF-β, the pan-HDAC inhibitor TSA was employed. The TGF-β stimulation increased the expression of the Atp1b1 gene in TSA-treated AETII cells (Figure 17). The MGCD0103 and MC1568 inhibitors were used to discriminate which class of HDAC enzymes was involved in the regulation of the Atp1b1 gene by TGF-β in mouse AETII cells. The Atp1b1 gene was released from the TGF-β-controlled repression exclusively in AETII cells co-treated with MGCD0103 (class I HDAC inhibitor). Conversely, use of the class II HDAC inhibitor, MC1568, did not influence the TGF-β-induced repression of the Atp1b1 gene (Figure 17). These data confirm a key role for class I HDACs in the repression of the ATP1B1 gene by TGF-β in alveolar epithelial cells.
4.10. Histone deacetylase inhibition rescues *Atp1b1* gene expression and decreases lung water content in the bleomycin model of acute respiratory distress syndrome

Several groups have reported TGF-β signaling to be deregulated and to mediate ARDS in human patients and lung injury in various animal models of ARDS (Budinger *et al.*, 2005, Wesselkamper *et al.*, 2005, Dhainaut *et al.*, 2003, Fahy *et al.*, 2003, Pittet *et al.*, 2001). Here, TGF-β signaling has been reported to employ HDAC2 to downregulate *ATP1B1* gene expression in A549 cells which could be alleviated by HDAC2 inhibition. Moreover, *Atp1b1* gene expression was downregulated in primary mouse AETII cells treated with TGF-β, and this effect was alleviated by HDAC inhibition. Therefore, the impact of the pan-HDAC inhibitor TSA on the expression of the *Atp1b1* gene in bleomycin model of ARDS has been investigated. Expression of the *Atp1b1* gene in murine lungs five days post-bleomycin instillation was reduced (Figure 18A) while lung water content was increased (Figure 18B). Remarkably, administration of the TSA to bleomycin-instilled mice restored the expression of the *Atp1b1* gene (Figure 18A). Moreover, increased *Atp1b1* gene expression by TSA was accompanied by decreased lung water (Figure 18B) when compared to bleomycin-only treated mice. Based on these
data, it can be concluded that histone deacetylases mediate the repression of the Atp1b1 gene in vivo and are involved in modulation of pulmonary edema.

![Graph A](image1.png)

![Graph B](image2.png)

**Figure 18.** Effect of trichostatin A on Atp1b1 gene expression and pulmonary edema in the bleomycin model of acute respiratory distress syndrome. C57BL/6J mice were instilled with bleomycin to initiate lung injury. At 24 h later, mice received intraperitoneal injection of trichostatin A (TSA) or vehicle for four subsequent days. After animals were sacrificed, RNA was isolated and Atp1b1 gene expression was analyzed by qPCR (A) and lung edema level was evaluated by the gravimetric method and expressed as lung wet-to-dry ratio (B). Data are expressed as mean ± SEM (n=5-8, per group).

4.11. Trichostation A does not decrease alveolar-capillary barrier permeability in bleomycin-treated mice

The impact of the TSA on alveolar-capillary barrier function in the bleomycin ARDS model was assessed by measurement of the total protein concentration in the BAL fluid and by Evans blue extravasation assay. As depicted in Figure 19A and 19B, bleomycin instillation induced the accumulation of protein in the BAL fluid and increased permeability of the endothelial barrier to Evans blue dye. However, TSA treatment did not decrease total protein levels in BAL fluid and did not reduce the Evans blue index. These data indicate that TSA does not affect permeability of the alveolar-capillary barrier in the bleomycin model of ARDS.
Figure 19. Effect of trichostatin A on alveolar-capillary barrier permeability in the bleomycin model of acute respiratory distress syndrome. C57BL/6J mice were instilled with bleomycin to initiate lung injury. At 24 h later, mice received intraperitoneal injection of trichostatin A (TSA) or vehicle for four subsequent days. The alveolar-capillary barrier permeability was analyzed by measurement of the total protein concentration in the broncho-alveolar lavage fluid (A) and Evans blue extravasation assay (B). Data are expressed as mean ± SEM (n=3-5, per group).

4.12. The inflammatory response is not modified by histone deacetylase inhibition in the bleomycin model of acute respiratory distress syndrome

Alveolar macrophages, neutrophils and lymphocytes mediate the inflammatory response in ARDS. The differential analysis of the inflammatory cells in BAL fluid revealed that bleomycin instillation decrease the number of alveolar macrophages and promoted neutrophil and lymphocyte recruitment to the lung in bleomycin model of ARDS (Figure 20). However, the treatment with TSA did not increase the percentage of alveolar macrophages (Figure 20A) and did not reverse neutrophil and lymphocyte sequestration to the alveoli after bleomycin instillation (Figure 20B and 20C). These data indicate that histone deacetylases do not mediate inflammatory responses in the bleomycin model of ARDS.
Results

Figure 20. The effect of trichostatin A on inflammatory responses in the bleomycin model of acute respiratory distress syndrome. C57BL/6J mice were instilled with bleomycin to initiate lung injury. 24 h later, mice received an intraperitoneal injection of trichostatin A (TSA) or vehicle for four subsequent days. After animals were sacrificed, the BAL fluid was collected and cells were recovered by cytospin centrifugation. Mean % of alveolar macrophages (A), neutrophils (B) and lymphocytes (C) in BAL fluid was identified by differential staining. Data are expressed as mean ± SEM (n=5, per group).
5. Discussion

The current concept of the pathological mechanisms at play in ARDS highlight the causative role of deregulated Na⁺ transporting machinery which negatively impacts AFC and, therefore, promotes the persistence of pulmonary edema (Sartori and Matthay, 2002). The TGF-β is widely recognized as a critical mediator of ARDS pathogenesis, and the involvement of the TGF-β pathway in disruption of Na⁺ transport and pulmonary edema formation has been established (Wesselkamper et al., 2005, Budinger et al., 2005, Fahy et al., 2003, Pittet et al., 2001). In this study, the question has been asked whether the expression of Na,K-ATPase subunit-encoding genes are differentially regulated in ARDS and if whether TGF-β can modulate expression of Na,K-ATPase subunits-encoding genes.

The comparison of in vivo and in vitro expression patterns revealed that FXYD1 and ATP1B1 genes were similarly regulated in lung tissues from patients with ARDS, and in TGF-β-treated A549 cells. The expression of the FXYD1 gene was significantly upregulated in lungs from ARDS patients and in TGF-β-stimulated cells, when compared to control samples. The auxiliary subunit FXYD1 regulates Na,K-ATPase function in a tissue-specific context. The FXYD1 protein has been shown to decrease the apparent Na⁺ and K⁺ affinity of Na,K-ATPase (Geering, 2006). Moreover, FXYD1-deficient mice exhibit increased Na,K-ATPase activity in cardiomyocytes which suggests that the upregulated FXYD1 gene expression observed in ARDS might contribute to decreased Na⁺ transport across the alveolar epithelium (Geering, 2008).

The ATP1B subunit is a critical component of the Na,K-ATPase complex and ATP1B1 is the most abundantly expressed isoform in the lung (Flodby et al., 2012). In the present study, expression of the ATP1B1 gene was demonstrated to be reduced in the lungs from ARDS patients and in TGF-β-treated A549 cells when compared to healthy lungs and untreated cells, respectively. A parallel trend was observed in the bleomycin model of ARDS and in primary mouse AETII cells treated with TGF-β. Furthermore, downregulation of Atp1b1 gene expression has been also reported in a nickel model of ARDS (Wesselkamper et al., 2005). These data indicate that repression of the ATP1B1 gene expression is a common reaction of the lung epithelium to injury.
5.1. The expression of the *ATP1B1* gene is strictly regulated by TGF-β

The main focus of this study was to understand the mechanism of *ATP1B1* gene repression by the TGF-β pathway. Doses of TGF-β employed in the present study (up to 10 ng/ml) were chosen to simulate pathological situation of ARDS where TGF-β was reported at a concentration of 7-14 ng/ml in BAL fluid (Budinger *et al.*, 2005, Dhainaut *et al.*, 2003, Fahy *et al.*, 2003). The recognition of the ligand by the membrane-bound receptors marks the initiation of TGF-β signaling and immediately leads to activation of the secondary messengers, the SMAD transcription factors (Massagué and Gomis, 2006). In the present study, inhibition of the TBRI receptor by SB431542 prevented SMAD2 and SMAD3 phosphorylation, and abolished downregulation of the *ATP1B1* gene. Furthermore, specific knock-down of SMAD2 and a common partner SMAD4, but not SMAD3, rescued *ATP1B1* gene expression. Together, these results demonstrate a central role of SMAD transcription factors in *ATP1B1* gene regulation and indicate that a complex consisting of SMAD2/SMAD4 rather than SMAD3/SMAD4 mediates TGF-β-controlled repression of the *ATP1B1* gene.

Apart from SMADs, TGF-β signaling utilizes a variety of other transcription factors to control the gene expression. The siRNA-mediated knock-down of SNAI1 and E2F5, but not of YY1, RUNX2, SNON and E2F4, prevented downregulation of *ATP1B1* gene expression in response to TGF-β. Chen and colleagues investigated in the detail the interaction between SMAD2, SMAD3 and E2F5 and reported a critical role of a complex consisting of these proteins in the repression of the *c-myc* gene by TGF-β (Chen *et al.*, 2002). Analysis of the *ATP1B1* promoter sequence in the present study revealed the presence of a region located at -2118 to -2110 bp upstream from transcription start site, which was highly similar to the E2F5 binding element characterized in the *c-myc* gene. The association of SNAI1 with SMAD3 and SMAD4 has been reported to play a critical role in repression of *CAR, OCCLUDIN, CLAUDIN-3* and *E-CADHERIN* genes in TGF-β-driven epithelial-to-mesenchymal transition (Vincent *et al.*, 2009). More importantly, SNAI1 has been demonstrated to bind the noncanonical E-box element located in the -71 to -66 bp region upstream from the transcriptional start site of the *ATP1B1* gene, and repress this gene expression in poorly differentiated carcinoma cell lines (Espineda *et al.*, 2004). However, the TGF-β-responsive *ATP1B1* promoter region (-3075 to -1238 bp) cloned for the purpose
of this study, lacked a noncanonical E-box element located within the -71 to -66 bp region upstream from the transcriptional start site. A bioinformatic analysis of the cloned ATP1B1 promoter sequence identified another noncanonical E-box element, located in the region -1562 to -1557 bp upstream of the transcriptional start site. Since SNAI1 has been shown here to mediate TGF-β-induced repression of the ATP1B1 gene, one can speculate that the noncanonical E-box element located within the -1562 to -1557 bp region upstream of the transcriptional start site might be alternative site recognized by SNAI1. Collectively, evidence presented here and in previously published studies indicate that SMAD2, SMAD4, SNAI1 and E2F5 are involved in ATP1B1 gene repression by TGF-β.

5.2. TGF-β signaling employs epigenetic machinery to regulate the ATP1B1 gene

In addition to recruitment of DNA-binding transcription factors, TGF-β signaling employs epigenetic machinery to regulate the expression of target genes (Feng and Derynck, 2005). Here, the involvement of DNA methylation in the regulation of the ATP1B1 gene by TGF-β was investigated. The inhibition of DNA methylation by 5-Aza-2'-dC resulted in the loss of the ability of TGF-β to modulate ATP1B1 gene transcription and promoter activity. These data suggest that TGF-β may regulate the ATP1B1 gene by altering the DNA methylation pattern. Interestingly, the use of 10 μM 5-Aza-2'-dC reduced ATP1B1 gene transcription and promoter activity in both TGF-β-treated as well as in control cells to the same level as in cells stimulated with TGF-β only. This observation may indicate that DNA methylation in the ATP1B1 gene promoter is important for normal expression of this gene under normal conditions. Additionally, Thillainadesan and colleagues recently reported that TGF-β signaling recruits the DNA-demethylating machinery which has a functional impact on p15ink4b gene expression (Thillainadesan et al., 2012). Therefore, it may be possible that TGF-β employs a DNA-demethylating complex to actively demethylate the ATP1B1 promoter and repress the ATP1B1 gene expression.

Regulation of histone acetylation is another epigenetic mechanism which can serve to modulate the gene expression (Wu and Grunstein, 2000). Several TGF-β associated transcription factors have been shown to recruit HDACs and to form functional complexes in order to repress target genes (Massagué et al., 2005). Treatment
with the pan-HDAC inhibitor TSA released the ATP1B1 gene from TGF-β-mediated repression in A549 cells and in primary mouse AETII cells, clearly indicating that TGF-β downregulates ATP1B1 gene by utilizing HDACs. Furthermore, the use of class-specific HDAC inhibitors revealed that class I but not class II HDACs are involved in the downregulation of the ATP1B1 gene expression and promoter activity by TGF-β. Further investigations elucidated a specific role for the class I HDAC member, HDAC2, in the ATP1B1 gene repression. As HDAC2 has been detected in the alveolar epithelium, the TGF-β/HDAC2 axis could perhaps facilitate repression of the ATP1B1 gene in vivo (Yin et al., 2006). Additionally, the importance of HDAC2 in the context of lung disease has already been stressed in pathogenesis of COPD (Barnes, 2009). The mechanism of HDAC-dependent gene repression involves the deacetylation of the histone proteins associated with the gene promoter region. The activity of the ATP1B1 promoter was preserved in cells co-treated with TSA and TGF-β, implying that the repressive histone deacetylation occurs within the -3075 to -1238 bp region upstream from the transcriptional start site. Results of the ChIP experiments demonstrated that HDAC2 interacts with the region located between -1339 to -1241 bp upstream from the transcriptional start site of the ATP1B1 gene. While the apparent HDAC2 abundance on the promoter was not increased after TGF-β treatment, TGF-β induced HDAC2 phosphorylation at serine 394. The HDAC2 has been found to be regulated by phosphorylation at serine 394 which potentates enzymatic activity and is an essential step during the formation of repressor complexes (Tsai and Seto, 2002). These results indicate that TGF-β executes ATP1B1 gene repression by inducing HDAC2 activity rather than promoting sequestration of additional HDAC2 molecules to the promoter region.

In the present study, SMAD2, SMAD4, E2F5, SNAI1 and HDAC2 were reported to mediate repression of the ATP1B1 gene in response to TGF-β. While direct interaction between HDAC2 and SMAD2, SMAD4 or E2F5 has not previously been reported, SNAI1 has been demonstrated to directly interact with HDAC2 on the E-CADHERIN promoter (Peinado et al., 2004). As mentioned above, SNAI1 was reported to repress the ATP1B1 gene, and the TGF-β-induced interaction between SNAI1 and SMADs has been documented (Vincent et al., 2009, Espineda et al., 2004). Based on this evidence, it is reasonable to hypothesize that SMAD2, SMAD4 and SNAI1 together with HDAC2 mediate the repression of the ATP1B1 gene expression by the TGF-β.
5.3. The inhibition of histone deacetylases rescues *Atp1b1* gene expression and reduces pulmonary edema

The availability of the ATP1B subunits is a rate limiting factor for Na,K-ATPase assembly and activity, since ATP1A subunits alone are unable to integrate into the cell membrane (Geering, 2008, Barquin *et al.*, 1997). Taking into account the fundamental role of ATP1B1 in the regulation of Na,K-ATPase, one can hypothesize that downregulation of *ATP1B1* gene expression in ARDS, and in the bleomycin model of this disease reported here, may prevent resolution of pulmonary edema by impairing Na⁺ transport and AFC. The importance of the *Atp1b1* gene in the regulation of the lung water homeostasis has been confirmed in *Atp1b1* gene knock-out mice, which displayed a major reduction in the AFC (Flodby *et al.*, 2012). Additionally, experiments on primary mouse alveolar epithelial cell monolayers lacking the *Atp1b1* gene demonstrated decreased transepithelial Na⁺ conductance (Kim *et al.*, 2011).

*In vitro* experiments presented in this study provide strong evidence for a key role for the HDAC2 in *ATP1B1* gene repression by TGF-β. Therefore, the possibility that HDAC inhibition would prevent *Atp1b1* gene repression in bleomycin-instilled mice has been tested. Treatment with TSA reversed downregulation of *Atp1b1* gene expression in the bleomycin model of ARDS. In parallel, animals co-treated with bleomycin and TSA displayed decreased lung wet-to-dry mass ratio. This observation signifies the presence of an inverse relationship between levels of *Atp1b1* gene expression, and levels of pulmonary edema, and indicates a beneficial effect of increased *Atp1b1* gene expression on AFC. Furthermore, the augmented expression of the *Atp1b1* gene by gene transfer has already been shown to significantly boost the Na⁺ transport, AFC clearance and improve pulmonary edema (Adir *et al.*, 2003, Azzam *et al.*, 2002, Stern *et al.*, 2000, Factor *et al.*, 2000, Factor *et al.*, 1998).

Collectively, these data indicate that reduced *Atp1b1* gene expression may be involved in water persistence in lungs of bleomycin-instilled mice and restored expression of the *Atp1b1* gene by TSA could augment Na,K-ATPase activity and AFC resulting in decreased edema. Moreover, the use of an HDAC inhibitor provided an alternative method to gene transfer to reactivate *Atp1b1* gene expression in order to reduce pulmonary edema. To date, HDAC inhibitors have been approved for the treatment of cutaneous T-cell lymphoma, and peripheral T-cell lymphoma and more than 80 clinical trials are currently evaluating the efficacy of over 11 different HDAC
inhibitors for the treatment of various malignancies (Ververis et al., 2013). Given the fact that only minor side effects were observed in these studies, it could be speculated that HDAC inhibitors could prove to be a valid pharmacological option for the treatment of ARDS.

In addition to the fundamental role in Na\(^+\) transport and AFC, the novel function of the ATP1B1 subunit in the maintenance of tight epithelial layers has been recently proposed (Vagin et al., 2012). Therefore, a reduction in the level of pulmonary edema by TSA could be achieved by increased AFC and/or reduced alveolar-capillary barrier permeability. However, since TSA treatment neither reduced protein content in the BAL fluid nor decreased albumin extravasation, it can be interpreted that HDAC inhibition does not improve alveolar-capillary barrier integrity but stimulates Na\(^+\) transport and effective AFC. This conclusion is supported by observations that ATP1B1 gene transfer does not reduce alveolar permeability to albumin in a rat model of acute hydrostatic pulmonary edema, regardless of restored Na\(^+\) transport and AFC (Azzam et al., 2002).

Despite that TSA decreased pulmonary edema, it cannot be excluded that mechanisms other than an Atp1b1-dependent increase in ion transport could restore lung water homeostasis. The possibility that TSA could improve lung water by reducing lung inflammation in the bleomycin model of ARDS was explored by characterization of the inflammatory cell profile in the alveolar space. Here, bleomycin instillation clearly provoked an inflammatory response in alveoli by increasing the fraction of the neutrophils and leukocytes, while decreasing the amount of alveolar macrophages. This dramatic change in the inflammatory cell profile by bleomycin remained unaffected by TSA treatment, implying that HDAC-mediated gene regulation does not alter the migration of inflammatory cells across the epithelial barrier. This finding is contrary to previously published results on HDAC inhibition effects in cecal ligation and puncture-induced polymicrobial sepsis and lipopolysaccharide model of ARDS. In these mice pre-treated with TSA or sodium butyrate HDAC inhibitors, neutrophil infiltration was reduced (Ni et al., 2010, Zhang et al., 2010). This discrepancy could be explained by the fact that Ni et al. and Zhang et al. used HDAC inhibitors as a preventive strategy before induction of lung injury, while in the present study, TSA was used 24 h after bleomycin instillation. Therefore, one could speculate that HDAC inhibition employed as a therapeutic approach has a limited effect on modulation of the inflammatory response. Finally, since HDAC inhibition neither altered inflammatory responses nor decreased protein levels in BAL fluid, improvement of pulmonary edema by TSA in the
bleomycin model of ARDS could be attributed to the increased AFC. The proposed mechanism of ATP1B1 gene repression by the TGF-β/HDAC2 axis in the context of AFC and ARDS has been summarized in Figure 21.

**Figure 21. Model of TGF-β/HDAC2-regulated ATP1B1 gene repression, decreased Na⁺ transport and impaired alveolar fluid clearance in acute respiratory distress syndrome.** Lung water balance is achieved by transepithelial Na⁺ transport mediated by ENaC and Na,K-ATPase. In acute respiratory distress syndrome, activation of TGF-β signaling causes repression of the ATP1B1 gene which is critically mediated by the epigenetic co-repressor HDAC2. Downregulation of the ATP1B1 subunit-encoding gene expression results in the decreased abundance of the Na,K-ATPase on the basolateral cell membrane and blocked Na⁺ transport. Consequently, reduced Na⁺ transport impairs alveolar fluid clearance (AFC) and promotes persistence of pulmonary edema. The inhibition of histone deacetylases by trichostatin A (TSA) rescues the ATP1B1 gene expression and allows the reinsertion of the Na,K-ATPase into cell membrane. This reactivates Na⁺ transport and potentiates AFC which ultimately reduces pulmonary edema.

In summary, data presented here advocate a key role for the TGF-β/HDAC2 axis in repression of the ATP1B1 gene in the alveolar epithelium in ARDS. TGF-β, a potent mediator of ARDS, activates HDAC2 which represses the ATP1B1 gene by direct
interaction with the promoter region. This HDAC2-mediated repression mechanism was sensitive to inhibition of histone deacetylation, which resulted in induction of ATP1B1 gene expression. Finally, HDAC inhibition also abrogated repression of the Atp1bl1 gene in bleomycin model of ARDS and decreased lung water content in parallel. As the Atp1bl1 gene performs essential role in efficient Na\(^+\) transport and AFC, it is tempting to conclude that HDAC inhibition and subsequent increase in the Atp1bl1 gene expression reduced pulmonary edema in bleomycin model of ARDS. Ultimately, data collected in the present study indicate that inhibition of HDACs in ARDS could be a viable therapeutic option to improve pulmonary edema in this currently incurable disorder.
V. Summary

Acute respiratory distress syndrome (ARDS) is a devastating disease characterized by high mortality with no available pharmacological therapy. Transforming growth factor (TGF)-β mediates ARDS by promoting formation and persistence of alveolar edema. The deregulation of the Na,K-ATPase, a key Na\(^+\) transporter in the alveolar epithelium, has been reported in ARDS, where impaired Na,K-ATPase function perturbs alveolar fluid clearance (AFC). In the present study, downregulation of \textit{ATP1B1}, a gene encoding an essential subunit of the Na,K-ATPase, has been observed in ARDS patients, bleomycin model of ARDS and in TGF-β-treated primary mouse alveolar epithelial type II cells and A549 cells. A mechanism of TGF-β-regulated repression of the \textit{ATP1B1} gene relied on SMAD2, SMAD4, SNAI1 and E2F5 transcription factors. Moreover, epigenetic machinery involving DNA methylation and action of histone deacetylases (HDAC) have been found to mediate the TGF-β-controlled downregulation of the \textit{ATP1B1} gene. The class I HDAC member, HDAC2, has been identified as a critical element involved in \textit{ATP1B1} gene repression, and has been observed to bind the \textit{ATP1B1} promoter and to be activated by TGF-β signaling. The treatment with the histone deacetylase inhibitor trichostatin A (TSA) rescued expression of the \textit{Atp1b1} gene in the bleomycin model of ARDS which was accompanied by decreased lung wet-to-dry ratio. However, TSA neither decreased alveolar-capillary barrier permeability nor alleviated inflammatory responses indicating that reduction of edema was attributable to restored Na\(^+\) transport and increased AFC.

These data describe a novel system of HDAC-regulated repression of the \textit{Atp1b1} gene by TGF-β which could be targeted and disrupted by HDAC inhibition in the bleomycin model of ARDS. Therefore, this study provides strong evidence to support the use of HDAC inhibitors in pharmacological therapy of ARDS.
VI. Zusammenfassung


Diese Daten beschreiben ein neues System einer HDAC-regulierten Reprimierung des *Atp1b1* Gens durch TGF-β, welches durch eine HDAC Inhibierung im Bleomycin Modell von ARDS gezielt angegriffen und umgekehrt werden kann. Daher liefert diese Studie einen starken Beweis der einen Einsatz von HDAC Inhibitoren in der pharmakologischen Therapie von ARDS rechtfertigen würde.
VII. Literature


VIII. Acknowledgements

I would like to express my appreciation to all following ones for their kind assistance during my PhD journey.

My first gratitude goes to my supervisor Dr. Rory Morty, who gave me a chance to work in his laboratory and who accepted me in the Molecular Biology and Medicine of the Lung international graduate programme. I am sincerely thankful for his guidance and enthusiasm during my research which ultimately made this thesis possible.

I would like to thank Prof. Dr. Werner Seeger, for giving me the opportunity to be in the Molecular Biology and Medicine of the Lung international graduate programme. I also would like to thank you for making me realise how dedication and passion of a single person can lead to biggest projects.

I am sincerely grateful to Dr. Malgorzata Wygrecka for her professional advice and stimulating discussions. Thank you for your understanding, patience and for helping me in realization of this project.

Simone Becker, Anna Blume, Jordi Ruiz Camp, Alicia Madurga Hernandez, Tatyana Likhoshvay, Ivana Mizikova, Gero Niess and Elpidoforos Sakkas, I would like to thank you all AG Morty lab members for your help, advice and many, many amusing moments. Monika Haselbauer and Ursula Reinhardt, thank you ladies for your invaluable assistance with administrative issues. It has been a great pleasure working with all of you!

I would like to thank Kasia for her love and patience which gave me strength to endure moments of doubt. Eryk, my son, thank you for sleeping through the night and for all these funny little moments every day you gave me. Finally, I would like to thank my parents and sister for their priceless support and faith in me.
The curriculum vitae was removed from the electronic version of the paper.
X. Declaration


_________________________  ___________________________
Ort, Datum                                                             Unterschrift